

**NEAR EAST UNIVERSITY**

**FACULTY OF MEDICINE**

**PHASE III**

**COURSE CATALOG**

**2022 – 2023**

# COORDINATOR

Fazilet Aksu, PhD, Prof.

Phone: /email: 0392 675 1000 Ext 3010/fazilet.aksu@neu.edu.tr

## ASSISTANT COORDINATORS

Ayşe Arıkan Sarıoğlu, PhD, Assoc. Prof.

E-mail: [aysearikan.sarioglu@neu.edu.tr](mailto:aysearikan.sarioglu@neu.edu.tr)

Neşe Akcan, MD, Assist. Prof.

E-mail: [nese.akcan@neu.edu.tr](mailto:nese.akcan@neu.edu.tr)

**For further details, please contact:**

Faculty of Madicine, Near East Boulevard Nicosia, TRNC via Mersin 10-Turkey

|  |  |
| --- | --- |
| Phone | +90 (392) 675 10 00 (Ext:3016 or 3030)  Email: medicine@neu.edu.tr |
|  |  |
|  |  |

## KEY LEARNING OUTCOMES OF THE MEDICAL EDUCATION PROGRAM

**Key Learning Outcomes**

**The student who successfully completes the program should be able to**

1. Define the basic structure, development and normal mechanisms of the human in terms of molecules, cells, tissues, organs and systems.
2. Investigate the abnormal structures and mechanisms in the human body, explain and evaluate the reasons of the diseases regarding the interaction of the individual with his environment.
3. Evaluate the processes of clinical decision making and management of the diseases with the guidance of evidence based medical practices.
4. Define the concepts of health and disease in the context of individual and society; health seeking and health promotion behaviors. national health care system and administrative processes.
5. Define the research process that is basic for medical knowledge, achieve the level of foreign language required to follow the developments in that area.
6. Take the history from the patient/applicant and his relatives.
7. Perform the physical examination of the individual, evaluates the diagnostic tests, manage the diagnosis and treatment processes using appropriate procedural steps.
8. Perform the medical procedures for diagnosis, treatment and prevention of the individuals.
9. Organize and archive the data on health and diseases gathered from the individuals and the community within the medical and administrative context.
10. Plan and perform the processes for the prevention and health promotion in the context of individuals and community.
11. Plan, conduct and evaluate the results of a scientific research.
12. Apply the principles of lifelong learning in following up the scientific and technological developments from a professional and public perspective.
13. Fulfill his responsibilities as a medical doctor regardless of any discrimination and in the framework of professional values, ethical principles, and legislations.
14. Take part in the teamwork with his colleagues and the other health care workers for the disease prevention and health promotion of the individuals and community.
15. Advocate for the health promotion, and development of health care services for the benefits of the individuals in the community.

**AIM AND LEARNING OBJECTIVES OF PHASE III**

**AIMS**

***Based on evidence***:

1. ***to refresh the information for***anatomy, histology and physiology of bodysystems,
2. ***to convey*** the information, related to body systems, on prevention of clinical conditions’ emergence, protection and improvement of health in healthyconditions.
3. **to point out**; at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute anemergency;
   1. ***to convey*** the required knowledge on risk factors, etiopathogenesis, physiopathology, andpathology,
   2. ***to convey*** knowledge onepidemiology,
   3. ***toconvey***knowledge onfrequentlyencounteredclinicalcomplaints,symptoms,signsandfindings, 3.4. ***to convey*** necessary knowledge on health care processes, clinical decision-making process, clinical decisions and clinical practices, with performance measures, for managing at the level of 7primary health careservice,
4. ***to convey*** the necessary information on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific bodysystem,
5. ***to convey the***knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific bodysystem,
6. ***to convey*** the recent methods on biostatisticalanalysis,
7. ***to convey the*** basic legal and ethical principles that should be followed in medicalpractice,
8. ***to equip with the*** basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medicalprofession.

**LEARNING OBJECTIVES**

***At the end of this phase, student should be able to***:

1.0. ***recall and use*** the necessary information fromanatomy, histology and physiology for the relevant body systems.

2.0. ***list the*** necessities for the prevention of clinical conditions’ emergence, protection and improvement of health in healthy conditions in relation to body systems.

3.0. ***explain*** the relevant risk factors and etiopathogenesis, at multisystem level or related to a body system, of clinical conditions which are frequent in the community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.

* 1. at cellular or tissuelevel,
  2. ***recognize*** the relevant morphologicalcharacteristics,
  3. ***show*** basic pathological changes that occur in clinicalconditions.
  4. at multi-system level or related to a body system, of clinical conditions which are frequent in the community and/or pose high risk for individual or community health, and/or life-threatening or constitute anemergency;
  5. ***explain*** mechanisms of destruction at the molecular, cellular, tisssue, organ, system, multi-system and organismallevel,
  6. ***describe the*** structural and functional changescaused by the disease, 5.3. ***list*** clinical progression of the diease.
  7. ***explain*** mechanisms of emergence for frequentlyencountered;
  8. clinicalcomplaints,
  9. symptoms,
  10. signs,
  11. laboratory and imaging findings of clinical conditions which are frequent in the community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.

7.0. at multi-system level or related to a bodysystem,

* for healthy conditions in an individual or community with a request,or
* in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in acommunity,
* forclinicalconditionswhicharefrequentincommunityand/orposehighriskfor individualorcommunity health, and/or life-threatening or constitute anemergency, ***explain*** in an evidence-based manner and with performance measures from the aspects of reliability, practicality andoutcomes,
* health careprocesses,
* acquisition of subjective or objective data, information and knowledge required for clinical decision making,
* clinical decision-makingprocess,clinical decisionsand • clinical practices which are required for management at primary health care service level. 7.1. practice of history taking and physical examination (*cardiovascularC3, pulmonary-C3, gastrointestinal-C4, gynecological-C7, breast-C7, neonatal, prepubertal/pubertal-C5, neurological/neuropsychiatric-C7, musculoskeletal-C8*)
  1. evaluation of emergency case (*sepsis and septic shock-C1, dyspnea-C2, acute abdominal pain- C4, urological emergencies-C7, neurological emergencies-C6,trauma-C8*)
  2. approach to healthy individual or patient (*fever-C1, cardiovascular disease-C3, chest pain-C3, cough and hemoptysis-C3, dyspnea-C3, anemia-C2, lymphadenopathy-C2, diarrhea-C4, pregnancy- C7, urinary tract infection-C7, neurological symptoms-C6, headache-C6, depression-C6, dementia-C6, musculoskeletaldysfunction-C8*) 7.4. laboratory and imaging tests/examinations
  3. making preliminary diagnosis or definitive diagnosisdecision
  4. making non-intervention or interventiondecision
  5. practicing non-intervention orintervention
  6. referral/transport of healthy individual orpatient

### PHASE III COURSE OBJECTIVES AND CONTENTS

**Infectious Diseases (course type: required; course code:MED 301)**

**Course Objective**: The student is expected to gain the knowledge and skills about important structural features and pathogenesis of medically-important microorganisms, main approaches to microbial diagnostics and treatment.

**Course content:** Medically-important bacteria, bacterial pathogenesis, diagnosis and treatment,Medically-important fungi, fungal pathogenesis, diagnosis and treatment, Medically-important parasites, pathogenesis, diagnosis and treatment, Medically-important viruses, viral pathogenesis, diagnosis and treatment, Signs and symptoms in infectious diseases

**Neoplasia and hematopoietic systems diseases (course type: required; course code:MED 302)**

**Course objectives**: Aim of this subject committee is to give the basic information and approaches related to hematopoietic and immune systems, and neoplasia.

**Course content**: Definition and classification of neoplasia. Characteristics of benign and malignant neoplasms. Etiology of neoplasia,epidemiology of cancer, dissemination and metastasis, molecular basis of cancer. Epithelial, mesenchymal tumors, skin tumors, teratomas and tumors of the nervous systems, Allergic, immunologic and anaphylactic reactions,Hemolytic anemia, iron deficiency anemia, aplastic-hypoplastic anemias, sickle cell anemia, Hematologic malignancies, Immunopathology,Cancer biochemistry,Pharmacological basis of cancer therapy. Antineoplastic drugs.

Biological effects of radiation.

**Cardiovascular &respiratory systems diseases (course type:required; course code: MED 203)**

**Course objective**: At the end of this committee, students are expected to learn basic knowledge and approach about cardiovascular and respiratory system pathologies and approach to diagnosis and treatment of those disorders.

**Course content:**The content of this committee includes epidemiology of cardiovascular and respiratory system disorders, pathological findings, clinical diagnosis and treatment principles as well as pharmacologic properties of commonly used drugs.

**Gastrointestinal system diseases (course type: required; course code: MED 304)**

**Course objective**: At the end of this committee students are expected to gain the basic knowledge regarding the mechanism behind the development of GIS diseases and the skills to diagnose and to treat them.

**Course content**: To evaluate the most common GI system disorders including the liver,bile tract and pancreas focusing on pathological,radiological,physiopathological and surgical aspect. Infectious diseases involving this system is also discussed.

**Endocrine and metabolism diseases (course type:required; course code: MED 305)**

**Course objective**: Promote understanding of the organization of the endocrine system, Provide that students understand the pathophysiology, clinical and laboratory findings of endocrine disorders, Facilitate students to apply that understanding to the investigation and management of patients with endocrine diseases.

**Course content**: Pharmacological and pharmacokinetics aspects of the hormones Clinical and laboratory features of hypophysial diseases and their treatments, The pathophysiology of the thyroid gland diseases, Clinical and laboratory features of thyroid gland diseases and their treatments Calcium and vitamin D metabolism,Vitamin deficiency Clinical and laboratory features of parathyroid gland diseases and their treatments.The pathophysiology, diagnosis, classification and clinical features of diabetes mellitus, its acute and chronic complications, the drugs which are used in its treatment. The pathophysiology and adrenal gland diseases. Clinical and laboratory features of adrenal gland diseases and their treatments. Clinical and laboratory features of polyglandular endocrine diseases.

**Neurological Sciences and Psychiatry Diseases (course type: required; course code: MED 306)**

**Course objective**: The aim of this block is to describe the pathophysiological basis and the clinical aspects of mainly the diseases of central and peripheral nervous system and mental health, eye, ear-nose-throat, with an introduction to the principles of clinical and radiological diagnosis, differential diagnosis, pharmacological and surgical treatment.

**Course Content**: Pathology of infectious, vascular, degenerative and neoplastic diseases of the nervous and musculoskeletal systems; basic pharmacology of drugs affecting the central and peripheral nervous system, anesthetics, drug abuse and dependence; clinical and radiological diagnosis and pathophysiological and therapeutic principles including surgery of the neurological, psychiatric, are the major subjects of this block. In addition, rheumotological diseases, osteoporosis and main topics in physical rehabilitation, general anesthesia, ophthalmology, and ear-nose-throat disorders will be introduced.

**Urogenital systems diseases (course type: required; course code: MED 307)**

**Course objective**: The course aims to provide an education in genitourinary system and breast diseases, including their epidemiologic, etiologic, pathogenetic, clinical and pathological features. It aims to develop knowledge in normal/abnormal menstrual cycle, infertility, contraception, pregnancy and obstetrics.

**Course content**: Menstrual cycle, pregnancy and obstetric information, reproductive endocrinopathies, contraception and infertility. Description of sexual assault and examination of sexually abused individual, sexually transmitted diseases. - Female and male sex hormones, contraceptive medications, anabolic steroids and antiandrogenic drugs; diuretics. - Diseases of vulva, vagina, uterus and ovary, and trophoblastic tumors. Breast diseases. Basic principles of renal physiology, evaluation of kidney functions, acute and chronic renal failure, proteinuria, acid-base and electrolyte imbalances. Renal glomerular, tubulointerstitial and vascular diseases, hypertension, kidney in systemic diseases. Congenital and acquired urologic diseases, obstructive uropathies, urolithiasis. Urogenital tumors. Radiology of urogenital system and nuclear uro-nephrology.

**Musculo-skeletal systems diseases (course type: required; course code: MED 308)**

**Course objective**:the disturbances affecting musculoskeletal system, with an introduction to the principles of clinical and radiological diagnosis, differential diagnosis, pharmacological and surgical treatment.

**Course content**: musculoskeletal disorders common in children and adults.

**Public Health- Forensic medicine-Deontology- Biostatistics ( course type: compulsory; course code: MED 309**

**Course objective:**At the end of this course, students will gain knowledge about publichealth, forensic medicine, medical ethics and biostatistics.

**Course content:** Introduction to public health, importance of public health, primary healthcare, social determinants of health, global health administration and organisation, introduction to epidemiology, definition, strategy and implementation ofepidemiology, classification of epidemiological studies, planning an epidemiological studydiagnostic and screening tests, health measurements, investigation of epidemics, control ofcommunicable diseases, control of diarrhoeal diseases, control of acute respiratory diseases,environmental health, environmental medicine, disaster medicine, reproductive health, community nutrition, healthy life skills, health education, health promotion, tobaccocontrol, health economics, international health, prevention and rehabilitation of disabilities,public health approach to ageing, noncommunicable (chronic) diseases, prevention ofaccidents and injuries, child and adolescent health, occupational health and diseases; researchplanning, sampling methods,measures of associations, linear ,nonlinear and logisticregression, survival analysis, evaluation of diagnostic tests; ethical issues confronted at thebeginning and at the end of life, research and publication,organ transplantation,genetics,clinical ethics case analysis, examination of the issues in terms of ethical and legal regulations; foensic sciences and autopsy, death and related issues, asphyxia related deaths, head trauma related injuries and death, human right violation cases.

**INDEPENDENT LEARNING**

**Description:**

Independent learning is also described as ‘personalised learning’, ‘student-centred learning’ and ‘ownership’ of learning and enables shifting of responsibility for the learning process from the teacher to the student. Independent learning

* has a vital role for continuing development of a system of school education that promotes high quality and lifelong learning and social equity and cohesion.

**Benefits of independent learning for students**

Indepent learning aims to achieve the following objectives:

* improved academic performance
* increased motivation and confidence
* greater student awareness of their limitations and their ability to manage them
* enabling teachers to provide differentiated tasks for students
* fostering social inclusion by countering alienation

**What a student should do for learning independently?**

|  |  |  |
| --- | --- | --- |
|  | **Strategies to Enable Independent**  **Learning (Crawford)** | **Activities to Structured Learning (Keste** |
| **S** | Select and focus topic and information needs. | Diagnose Need |
| **U** | Uncover potential sources of information. Learn how to access them. | Identify Learning Resources |
| **C** | Collect, examine, and select suitable resources. | Identify Learning Resources |
| **C** | Compile relevant information from selected sources. | Use Resources |
| **E** | Evaluate, interpret, analyze, and synthesize the information. | Use Resources |
| **E** | Establish and prepare an appropriate format and present the information. | Use Resources |
| **D** | Determine the effectiveness of the whole process. | Assess learning |

**References for further reading:**

1. http://www.leeds.ac.uk/educol/documents/193305.pdf
2. http://www.curee.co.uk/files/publication/%5Bsitetimestamp%5D/Whatisindependentlearningandwhatarethebenefits.pdf
3. https://westpoint.edu/sites/default/files/inlineimages/centers\_research/center\_for\_teching\_excellence/PDFs/mtp\_project\_papers/D eLongS\_09.pdf

### ASSESSMENT PROCEDURE

In the first three years of the medical faculty, students are evaluated by MCQ (multiple choice questions) exams, laboratory exams. Performance assessment is the only evaluation method used in the 6th year. During Phases 1, 2 and 3 a Subject Committee Examination is given at the end of each subject committee. These examinations consist of a written and a practical part. At the end of Phases 1, 2 and 3 there is also a final examination. Success in each committee exam is not sufficient to pass the year; the student must also successfully complete the final examination. If a student fails in the final exam s/he must take the re sit exam. Re sit exam is generally done in September, please follow the announcements done by the coordinator of each year (phase).

There is an examination at the end of each clinical clerkship in Phase 4 and 5. In general, the assessment examination is performed as theoretical (written and oral, written or oral) and practical (written and oral, written or oral). In the examination, the student's performance during the clerkship is taken into consideration as well. In Phase 6, the student's performance is evaluated according to his/her study and enthusiasm in the wards and outpatient clinics.

**Grading Scheme and Grades:**

|  |  |  |  |
| --- | --- | --- | --- |
| **SCORE** | **COURSE GRADE** | **GRADE POINTS** | |
| 90-100 | AA | 4,00 | (Excellent) |
| 80-89 | BA | 3,50 | (Excellent) |
| 70-79 | BB | 3,00 | (Very Good) |
| 60-69 | CB | 2,50 | (Very Good) |
| 50-59 | CC | 2,00 | (Good) |
| 45-49 | DC | 1,50 | (Failed) |
| 40-44 | DD | 1,00 | (Failed) |
| 35-39 | FD | 0,50 | (Failed) |
| 0-34 | FF | 0,00 | (Failed) |

#### ASSESSMENT PROCEDURE FOR PHASE III

The Assessment Procedure of the Phase III covers exams and scores and their abbrevations that shown below.

**Exams:** o Committee Exam (CE) o Final Exam (FE) o Make-up Exams (MUE) o Committee Score (CS) o Committee Average Score (AVG) o Good Medical Practice (GMP) o Final Exam Score (FES) o Year End Grade (YEG) o Grade Point Average (GPA)

All exam grades are between 0-100 points. Assessment approaches, assessment methods and assessment toolsrelated with the exams and score types, are described below.

In CEs, FEs and MUEs students are given a maximum of 100 (70-120) MCQs. In the FEs and MUEs the question numbers are 100. The number of questions for the CEs are determined according to the number of lectures in each subject committee. The general rule is one question per hour of lecture. However, when the lecture hours are more than 100 hours then the question numbers are adjusted to be 100 questions max. These MCQs are expected to be answered in 70-120 minutes depending on the number of questions on the exam. As a rule, 1 minute is given per question unless the questions are very long questions, in which case additional 5-10 minues are provided for that exam. In MED 301, laboratory practical exam contributes to the total grade of the exam and accounts for 10% of the CE grade. In laboratory practical examinations students are shown a slide of a microscopic image and are asked to identify the organism or a related question in a matter of 20 seconds per slide. There are usually 10 powerpoint slides per practical exam.In pathology lab practical, either a separate exam is done by the instructors or additional questions are placed as part of the CE.

The answer sheets are evaluated by an optic reader. 4 incorrect answers will cancel 1 correct answer. The CE score will be determined automatically by the computer using the following algorithym:

(The number of correct answers – (the number of wrong answers/4))x(100/y) where y is the number of questions in the CE.

Results of the laboratory exams (microbiology and pathology), whenever appropriate, will be added to the CE and will yield CS. The letter grades for the students will be assigned according to the table above. The students who obtained ≥ 50% (CC and better) will be considered as successful for that committee exam. However, even if a student fails a specific committee, it is the year end grade that determinesif a student passes the whole year. At the end of the completion of subject committees,the average CSs of the 9 committees (AVG) will be used for the calculation of year end grade or Term score (TS). The student’s grade for the FE or the MUE grade, which will replace the FE grade if the student has failed in the FES, will bu used for calculation of TS. Students will also get a grade for Good Medical Practice (GMP) – Max grade for this is 4%. The formula for calculating the year end grade or the Term score is as follows:

(AVG \* 0.6) + (FINAL \* 0.36) + GMP = Year End Grade

The students who obtained ≥ 50 % will be considered successful By using the year end grade and grades taken from all compulsory and elective courses, grade point average (GPA) will be calculated.

# EXAM RULES

* When entering all the exams, students are required to bring their student ID cards with them to the exam room. For the final exams, students are also required to bring their fee payment slips showing that they have paid their tuition fees. These are checked by the university’s security and students are not allowed to sit for their final exams if they do not have their payment slips or their student ID cards.
* The goal is to conduct valid and reliable exams. The formal exams should cover the learning outcomes.
* During exams, use of electronic devices (mobiles, intelligent wristwatches etc) is prohibited.
* Cheating in the exams cannot be tolerated. If a student is caught cheating, his paper will be signed by the invigilating instructor at the end of the exam. If the case is taken to the Disciplinary Committee of the Faculty, the student automatically fails the course.
* During the examination you should not talk, look around, attempt to signal or exchange objects of any kind without permission. If you attempt to cheat you will be recorded as having failed and disciplinary action will be taken against you.
* Once a student hands his or her examination papers and leaves the hall he or she may not return to the examination hall for any reason.
* You are not allowed to leave the examination room within the first 30 and last 15 minutes of the examination.
* Even if you think there are some erroneously printed questions you may not ask the examiners on duty anything about the questions.

**General information about the examination:**

* Examination will be graded by an optic reader. An answer sheet will be provided for recording your answers to all of the multiple choice questions. Each answer sheet has 200 fields and each field has 5 marking spaces (A) through (E). The questions are numbered to correspond to the fields and the answers correspond to marking spaces. When you have decided which answer is correct fill in the corresponding marking space on your answer sheet with a soft pencil. If you change your mind erase your first mark completely.
* Each question has one correct answer. For every four wrong answers one correct answer will be cancelled.
* Do not wrinkle, fold or tear your examination answer sheet.
* The question booklet as well as the answer sheet must be returned

Those students found to have committed academic misconduct will face administrative sanctions imposed by the administration of Near East University Faculty of Medicine according to the disciplinary rules and regulations of the Turkish

Higher Education Council (YÖK) for students. The standard administrative sanctions include, the creation of a disciplinary record which will be checked by graduate and professional life, result in grade “F” on the assignment, exams or tests or in the class. Students may face suspension and dismissal from the Near East University for up to one school year. In addition, student may loose any academic and non academic scholarships given by the Near East University for up to four years. The appropriate sanctions are determined by the Near East University administration according to egregiousness of the Policy violation.

The following is used as the booklet cover for each exam:

1. Students are requested to read carefully the following instructions, as noncompliance with them may lead loss of marks in the examination.

* 1. Time allowed for this examination is **\_\_** minutes.
  2. Check to be sure that your question booklet has **\_\_\_** questions and **\_\_\_** pages numbered consecutively.
  3. During the examination you should not talk, look around, attempt to signal or exchange objects of any kind without permission. If you attempt to cheat, you will be recorded as having failed and disciplinary action will be taken against you.
  4. Once a student hands his or her examination papers and leaves the hall he or she may not return to the examination hall for any reason.
  5. Even if you think there are some erroneously printed questions you may not ask the examiners on duty anything about the questions.

1. General information about the examination:
   1. This examination will be graded by an optic reader. An answer sheet will be provided for recording your answers to all of the multiple-choice questions. Each answer sheet has 200 fields and each field has 5 marking spaces (A) through (E). The questions are numbered to correspond to the fields and the answers correspond to marking spaces. When you have decided which answer is correct fill in the corresponding marking space on your answer sheet with a soft pencil. If you change your mind erase your first mark completely.
   2. Each question has one correct answer. For every four wrong answers one correct answer will be cancelled.
   3. Do not wrinkle, fold or tear your examination answer sheet.

## THE QUESTION BOOKLET AS WELL AS THE ANSWER SHEET MUST BE RETURNED

**WEEKLY COURSE SCHEDULE**

|  |  |
| --- | --- |
| **COURSE CODE** | **COURSE** |
| **MED 301** | **Infectious Diseases** |
| **MED 302** | **Neoplasia and Haemopoietic System**  **Diseases** |
| **MED 303** | **Cardiovascular and Respiratory System**  **Diseases** |
| **MED 304** | **Gastrointestinal System Diseases** |
| **MED 305** | **Endocrine and MetabolicDiseases** |
| **MED 306** | **Neurological Sciences and Psychiatric**  **Diseases** |
| **MED 307** | **Urogenital System Diseases** |
| **MED 308** | **Musculo-skeletal System Diseases** |
| **MED 309** | **Public Health** |

**TEXTBOOKS FOR FURTHER READING**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **NO** | **DEPARTMENT** | **TEXTBOOK** | **AUTHOR** | **PUBLISHER** |
| **1** | **Medical**  **Pharmacology** | Lippincott's Illustrated  Review of Pharmacology.  6th ed., | Harvey, Richard A. | Wolters Kluwer Health,  2015. ISBN-13: 978-14698-8756-2; ISBN-10:1-  4698-8756-8 |
| Katzung'sBasic&ClinicalP harmacology. 13th Edition. | Katzung,BertramG.,Master s,SusanB.,TrevorAnthonyJ  . | McGraw Hill Companies,  2015. ISBN-13:978-  0071825054  ISBN-10: 0071825053 |
| Goodman&Gilman’s The  Pharmacological  BasisofTherapeutics.Edit ors:12thEdition. | Brunton, Laurence,  Chabner, Bruce, Knollman, Bjorn. | McGrawHillCompanies,2011. ISBN-13:978-0071624428 |
| **2** | **Gastroeneterolo gy** | **Netter's Gastroenterology, 2nd Edition** | Martin H. Floch, MD and Neil R. Floch | **Elsevier:**  ISBN-13: 978-1437701210  ISBN-10: 1437701213 |
| **3** | **Obstetrics and Gynecology** | Williams Gynecology, 2016, 3rd ed. | Barbara L. Hoffman, John O. Schorge, Joseph I. Schaffer, Lisa M.  Halvorson, Karen D.  Bradshaw, F. Gary  Cunningham | McGraw Hill Companies |
|  |  | Williams Obstetrics, 25th ed. | Gary Cunningham,  Kenneth J. Leveno, Steven L. Bloom, Catherine Y.  Spong, Jodi S. Dashe,  Barbara L. Hoffman, Brian M. Casey, Jeanne S.  Sheffield | McGraw Hill Companies |
| **4** | **Public Health** | Oxford Textbook of Global Public Health, Sixth Edition | Detels R.,Gulliford M., Karim A.Q., Tan. C.C | Oxford University Press,  2015ISBN-13: 978-  0199661756  ISBN-10: 0199661758 |
|  |  | The New Public Health 3rd Edition | Theodore Tulchinsky Elena  Varavikova | Hardcover ISBN: 9780124157668 eBook ISBN: 9780124157675  Imprint: Academic Press  Published Date: 15th April  2014 |
| **5** | **General Surgery** | Sabiston Textbook of Surgery | Courtney Townsend R. Daniel Beauchamp B.  Mark Evers Kenneth  Mattox | Elsevier, 20th edition, 2016 |
|  |  | Schwartz’s Principles of Surgery | F. Charles Brunicardi, Dana  K. Andersen, Timothy R.  Billiar, David L. Dunn, Lillian  S. Kao, John G. Hunter,  Jeffrey B. Matthews,  Raphael E. Pollock | Professional Publishing, 11th edition, 2019 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **6** | **Urology** | Smith and Tanagho’s General Urology | Jack W McAnnich, Tom F. Lue. Lang | McGraw-Hill Professional Publishing, 18th Edition |
|  |  | Campbell-Walsh Urology  Urology Board Review, Pearls of Wisdom | Alan J. Wein ; editors, Louis R. Kavoussi | Elsevier 11th edition, 2016 |
|  |  |  | Stephen W. Leslie | McGraw-Hill Professional Publishing, 4th ed. 2013. |
| **7** | **Physical Therapy & Rehabilitation** | Brandon’s Physical medicine and rehabilitation | David X. Cifu | Elsevier, 5th ed. 2015 |
|  |  | DeLisa’s physical medicine and rehabilitation | Walter R Frontera et al. | Lippincott Williams & Wilkins, 5th ed. 2010 |
| **8** | **Orthopedics and Traumatology** | Mark D. Miller, Stephen R. Thompson | Miller’s review of orthopaedics | Elsevier, 7th ed. 2015 |
|  |  | Handbook of fractures | Kenneth A. Egol, Kenneth J. Koval, Joseph D.  Zuckerman | LWW; Fifth edition, 2014 |
| **9** | **Medical Pathology** | Robbins Basic Pathology (study smart with student consult) | Vinay Kumar, Abul K.  Abbas, Jon C. Aster | Elsevier Saunders  2017,**eBook**  **ISBN:** 9780323394147 **eBook ISBN:** 9780323394123 **eBook ISBN:** 9780323394130  **Hardcover**  **ISBN:** 9780323353175 |
|  |  | Robbins Basic Pathology (tenth edition) | Vinay Kumar, Abul K. Abbas, Jon C. Aster | Elsevier Saunders  2017,ISBN10 0323480543  ISBN13 9780323480543 |
|  |  | Text book of pathology (6th edition) | Harsh Mohan | Jaypee Brothers Medical  Publishers (P) Ltd,2019  ISBN: 978-81-8448-702-2 |
|  |  | Molecular Oncology: Cases of Cancer and Targets fort REATMENT (1ST edition) | Edward P.  Gelmann (Editor), Charles  L. Sawyers  MD (Editor), Frank J.  Rauscher III (Editor) | Cambridge University Press; 1 edition (February 17, 2014)  ISBN-10: 0521876621  ISBN-13: 978-0521876629 |
|  |  | Principles of Molecular Oncology (3rd Edition) | Miguel H.  Bronchud (Editor), MaryAn n Foote (Editor), Giuseppe Giaccone (Editor), Olufunm ilayo I.  Olopade (Editor), Paul Workman (Editor), K.  Antman (Foreword) | Humana Press; 3rd edition  (November 30, 2007)  ISBN-10: 9781934115251  ISBN-13: 978-1934115251  ASIN: 1934115258 |
| **10** | **Medical**  **Biochemistry** | Tietz Textbook of Clinical  Chemistry and Molecular  Diagnostics (5th edition) | Carl A. Burtis, David E.  Bruns, and Edward R.  Ashwood | Saunders, 2012 **eBook ISBN:** 9781455777112 **eBook ISBN:** 9781455727131 **eBook ISBN:** 9781455759422 |
|  |  | Medical Biochemistry (5th edition) | John W Baynes, Marek H.  Dominiczak | Elsevier; 5 edition (March 2,  2018) SBN-13: 978-  0702072994, ISBN-  10: 0702072990 |
|  |  | Clinical Chemistry: Concepts and Applications | Shauna C. Anderson and  Susan Cockayne | Waveland Press, Inc.; Revised edition (March 23, 2007) ISBN-13: 978-1577665144  ISBN-10: 1577665147 |
|  |  | Biochemistry (Lippincott  Illustrated Reviews Series) | Richarsd A. Harvey (editor) | LWW; Sixth, North American edition (June 1, 2013) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  | ISBN-10: 1451175620  ISBN-13: 978-1451175622 |
| **11** | **Medical**  **Microbiology** | Medical Microbiology (8th edition) | Patrick Murray Ken  Rosenthal Michael Pfaller | **Elsevier, 2015. Paperback ISBN:** 9780323299565 **eBook ISBN:** 9780323359528 **eBook ISBN:** 9780323359498 **eBook ISBN:** 9780323359511 **eBook ISBN:** 9780323388504 |
|  |  | Principles of Molecular  Microbiology (6th edition) | Alan Cann | Elsevier, Academic Press,  2015. **Paperback ISBN:** 9780128019467 **eBook ISBN:** 9780128019559 |
|  |  | Manual of Clinical  Microbiology | James H.  Jorgensen (Editor), Michael  A. Pfaller (Editor) | ASM Press; 11 edition (April  30, 2015) ISBN10: 9781555817374 ISBN-13: 978-1555817374  ASIN: 1555817378 |
| **12** | **Cardiology** | Hurst’s the Heart, 14th Edition: two volüme set | Valentine Fuster, Robert A.  Harrington, Jagat  Narula, Zubin J. Eapen | McGraw-Hill Education /  Medical; 14 edition (April 11,  2017) ISBN-13: 978-  0071843249  ISBN-10: 0071843248 |
|  |  | Swanton’s cardiology: A concise guide to clinical pratice (6th edition) | R. Howard Swanton, Shrilla Banerjee | Wiley-Blackwell; 6th edition  (29 Feb. 2008)  ISBN-10: 1405178191  ISBN-13: 978-1405178198 |
| **13** | **Pulmonary Medicine** | Principles of Pulmonary Medicine | Steven Weinberger Barbara  Cockrill Jess Mande | Elsevier2018, **Paperback ISBN:** 9780323523714 **eBook ISBN:** 9780323523738 **eBook ISBN:** 9780323523721 **eBook ISBN:** 9780323547123 |

**COMMITTEE I – 301 Infectious Diseases Committee**

## AIMS and LEARNING OBJECTIVES

**AIMS**

1. ***1. to remind***knowlegde on pattern of infectious agents that cause clinical conditions which are endemic in the population and might be a risk for individual or society, and/or life-threaating or constitue an emergency.
2. ***to convey*** knowlegde on epidemiology of infectious agents that cause clinical conditions which are endemic in the population and might be a risk for individual or society, and/or life-threaating or constitue an emergency.
3. ***to convey*** knowledge on pathogenesis mechanisms of infectious agents that cause clinical conditions which are endemic in the population ans might be a risk for individual or society, and/or life-threaating or constitue an emergency.
4. ***to convey*** sufficient knowledge on preventive approaches of infectious agents that cause clinical conditions, and protection or improvement of health against these conditions,
5. ***to convey*** knowledge on mechanisms of the most frequenct infectious agensts that cause clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. ***to convey*** sufficient knowledge on pharmaceutical drugs which are used in infectious clinical conditions.
7. ***to convey*** fundemental knowledge on genetics of infectious agents and their clinical conditions,

**LEARNING OBJECTIVES**

1. ***explain*** knowlegde on pattern of infectious agents that cause clinical conditions which are endemic in the population and might be a risk for individual or society, and/or life-threaating or constitue an emergency.
2. ***explain*** structure andmechanisms of pathogenesis of infectious agenets (bacteria, viruses, fungi, parasites, prions) that cause clinical conditions which are frequent in the population and might be a risk for individual or society, and/or life-threaating or constitue an emergency.
3. ***classify*** infectious agents that cause clinical conditions which are endemic in the population and might be a risk for individual or society, and/or lifethreaating or constitue an emergency, based on causative agents and systems,
4. ***explain***structural and functional mechanisms in molecular, cellular, tissue, (multi-) system and organismal levelof infectious agenets that cause clinical conditions which are frequent in the population and might be a risk for individual or society, and/or life-threaating or constitue an emergency.
5. ***explain***hostimmuneresponse mechanisms and consequencesinfectious agents that cause clinical conditions which are endemic in the population and might be a risk for individual or society, and/or life-threaating or constitue an emergency, based on causative agents and systems,
6. ***explain*** epidemiology of infectious agents that cause clinical conditions which are endemic in the population and might be a risk for individual or society, and/or life-threaating or constitue an emergency, based on causative agents and systems,
7. ***explain*** (current)preventive strategies of infectious clinical conditions, and protection or improvement of health against these conditions, in healthy or susceptible individual or community,
8. ***explain*** pharmacological actionmechanisms such as resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial, antifungal, antiviral, antiprotozoal, antihelmintic drugs,

antiseptics and disinfectants) used in infectious clinical conditions,

1. ***explain*** hereditary immune system disorders,

40

**COMMITTEE I – INFECTIOUS DISEASES PROGRAM**

## 301 Infectious Diseases Committee

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Theoretical** | **Practical** | **Discussion** | **Total** |
| **Medical Biochemistry** | **2** |  |  | **2** |
| **Medical Microbiology** | **80** | **19** |  | **99** |
| **Medical Pathology** | **6** |  |  | **6** |
| **Medical Pharmacology** | **28** |  |  | **28** |
| **Pediatrics** | **5** |  |  | **5** |
| **Internal Medicine** | **1** |  |  | **1** |
| **Nuclear Medicine** | **1** |  |  | **1** |
| **Clinical and Professional Development** |  | **4** |  | **4** |
| **TOTAL** | **123** | **23** |  | **146** |

**st**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | | | **FRIDAY** |
| **9.00 – 09.50** | Bacterial virulence factors and  pathogenicity | Drug receptors I | Immunity to microbes I | Pharmacodynamic drug interactions | | | Enterobacteriacea e I |
| **10.00 – 10.50** | Bacterial virulence factors and  pathogenicity | Drug receptors II | Immunity to microbes II  Umut Gazi | Pharmacokinetic drug interactions | | | Enterobacteriacea  e II |
| **11.00 – 11.50** | Normal flora | Eicosanoids: Prostaglandins, leucotrienes and antagonists I | Doseconcentrationeffect relationship  I | Food allergy | | | Subcutaneous mycoses |
| **13.00 – 13.50** | Nosocomial infections | Eicosanoids: Prostaglandins, leucotrienes and antagonists ıı | Doseconcentrationeffect relationship  II | Drug allergy | | | True systemic mycoses |
| **14.00 – 14.50** | Introduction to  Phase III and Mechanisms  of drug action | Scintigraphic imaging in infectious diseases | Introduction to medical mycoses | Autocoids: Histamine and serotonin I | | | Introduction to medical virology |
| **15.00 – 15.50** | Immunopathoge-  nesis of allergic disorders I | Streptococci and  enterococci I | Superficial mycoses | Autocoids: Histamine and serotonin II | | | Diagnostic procedures in viral infections |
| **16.00 – 16.50** | Immunopathogenesis of allergic disorders II | Streptococci and enterococci II | Introduction to pathology of infectious disease and bacterial infections I |  | Staphylococci |  | Mycobacteria I |
|  |
| **17.00 – 17.50** | **Independent learning** | **Independent learning** | Introduction to pathology of infectious disease and bacterial  infections II | Gram positive,  non-spore forming  bacilli | | | Mycobacteria II |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **9.00 –**  **09.50** | Introduction to parasitology I | Actinomyces andNocardia | Tissue protozoa  (Toxoplasma) | Entomology  (Insects) | Molecular methods in clinical microbiology |
| **10.00 –**  **10.50** | Introduction to  parasitology II | Gram-positive, aerobic sporeforming bacilli | Tissue protozoa  (Leishmania &  Trypanasoma) | Entomology  (Arachnoides) | Other systems cestodes |
| **11.00 –**  **11.50** | Mucosal immunity | Brucella | Anaerobic bacteria I | LAB: Cultivation of clinical specimens and examination of cultures | Clinical presentation of parasite caused diseases& review I |
| **13.00 –**  **13.50** | Amoebae species | Clinical manifestations of  infectious diseases | Anaerobic bacteria II | **Independent learning** | Clinical presentation of parasite caused diseases& review II  Ayşegül Taylan  Özkan |
| **14.00 –**  **14.50** | Free living  amoebeas and blastocystis | Flagellates and ciliates | GIS nematodes | GIS trematodes | LAB: Diagnosis of parasitic infections in blood samples &  arthropodes I |
| **15.00 –**  **15.50** | Salmonella, shigella,yersini  a I | Opportunistic protozoa | Other systems nematodes | Other systems trematodes | LAB: Diagnosis of parasitic infections in blood samples &  arthropodes II |
| **16.00 –**  **16.50** | Salmonella,  shigella,yersini a II | Blood protozoa | Filarial  nematodes | GIS cestodes | LAB: Diagnosis of parasitic infections in fecal samples I |
| **17.00 –**  **17.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | LAB: Diagnosis of parasitic infections in fecal samples II |

**rd**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **9.00 – 09.50** | Introduction to antibiotics I (history, terminology,  classification) | Vasoactive peptides | Campylobacter and Helicobacter | Non-fermentative bacteria | Macrolides, ketolides, lincosamides, and tetracylines |
| **10.00 – 10.50** | Introduction to antibiotics II  (Resistance | Pathology of fungal, parasitic and viral diseases | Vibrio,  Plesiomonas and  Aeromonas | Haemophilus and  Bordetella | Chloramphenicol , streptogramins, sulphonamides and trimetoprim- sulfomethoxazol e) |
| **11.00 – 11.50** | Clinical biochemistry of body fluids I | Active and passive immunization I | Herpes viruses I | Narrow-spectrum antistaphylococcal s  (vancomycines, and teikoplanins) | Rhabdoviruses |
| **13.00 – 13.50** | Clinical biochemistry of body fluids II | Active and passive immunization II | Herpes viruses II | Aminoglycosides quinolones and agents used for  UTI | Arboviruses |
| **14.00 – 14.50** | Combined and prophylactic antibiotic usage | Good Medical  Practice | Beta lactam antibiotics II  (cephalosporins, monobactams) | Nosocomial infections and prevention I | Rabies: Clinical manifestations and treatment |
| **15.00 – 15.50** | Beta lactam antibiotics I  (penicilins) | Good Medical  Practice | Beta lactam  antibiotics III  (Carbapenems,  Inhibitors of beta lactamase) | Nosocomial infections and prevention II | Neisseria and  Moraxella |
| **16.00 – 16.50** | LAB:  Examination of gram-positive cocci | Good Medical  Practice | Antihelmintic drugs | LAB:  Examination of mycobacteria | Spirochetes |

**Subject Committee: 301 4th**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **9.00 – 09.50** | Hepatitis viruses  I | LAB:  Examination of  Neisseria | **WHITE COAT CEREMONY** | Picorna viruses I | Respiratory viruses and  influenza I |
| **10.00 – 10.50** | Hepatitis viruses  II | LAB:  Antibiotic susceptibility tests | **WHITE COAT CEREMONY** | Picorna viruses II | Respiratory viruses and influenza II |
| **11.00 – 11.50** | Chemotherapy of tuberculosis | LAB:  Normal microbial flora of human body I | **WHITE COAT CEREMONY** | LAB:  Normal microbial flora of human body II | **Independent learning** |
| **13.00 – 13.50** | Antifungal drugs | LAB:  Examination of Enterobacteriacea  e I | **WHITE COAT CEREMONY** | LAB:  Examination of Enterobacteriace  ae II | Pathology of granulomatous inflammatory diseases I |
| **14.00 – 14.50** | Collection, transportation and evaluation of specimens in microbiology | Oncogenic viruses | **WHITE COAT CEREMONY** | Antiviral drugs | Pathologyof granulomatous inflammatory diseases II |
| **15.00 – 15.50** | Opportunistic mycoses I | HIV | **WHITE COAT CEREMONY** | Amyloidosis | LAB:Diagnosis of viral infections |
| **16.00 – 16.50** | Opportunistic mycoses II | **Independent learning** | **WHITE COAT CEREMONY** | **Independent learning** | LAB: Serological tests |
| **17.00 – 17.50** | **Independent learning** | **Independent learning** | **WHITE COAT CEREMONY** | **Independent learning** | **Independent learning** |

**Subject Committee: 301 5thWeek of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **9.00 – 09.50** | Antiprotozoal  drugs I | LAB: Examination of dermatophytes and fungi frequently encountered in opportunistic mycosis  I | **Independent learning** | **Independent learning** | **Independen**  **t learning** |
| **10.00 – 10.50** | Antiprotozoal drugs II | LAB:Examination of dermatophytes and fungi frequently encountered in opportunistic mycosis  II | **Independent learning** | **Independent learning** | **Independen**  **t learning** |
| **11.00 – 11.50** | Measles, mumps and rubella viruses | Prion diseases | **Independent learning** | **Independent learning** | **Independen t learning** |
| **13.00 – 13.50** | Adeno and poxviruses | **Independent learning** | **Independent learning** | **Independent learning** | **Independen**  **t learning** |
| **14.00 – 14.50** | Pathologyof granulomatous inflammatory diseases III | **Independent learning** | **Independent learning** | **Independent learning** | **Independen t learning** |
| **15.00 – 15.50** | Chlamydia,  Mycoplasma and  Ureoplasma | **Independent learning** | **Independent learning** | **Independent learning** | **Independen t learning** |
| **16.00 – 16.50** | Rickettsia and  Ehrlichia | **Independent learning** | **Independent learning** | **Independent learning** | **Independen t learning** |
| **17.00 – 17.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Independen t learning** |

**Subject Committee: 301 6th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **9.00 – 09.50** |  |  |  |  |  |
| **10.00 – 10.50** | **Laboratory**  **Examination** |  |  |  |  |
| **11.00 – 11.50** | **Committee Examination** |  |  |  |  |
| **13.00 – 13.50** | **Committee Examination** |  |  |  |  |
| **14.00 – 14.50** |  |  |  |  |  |
| **15.00 – 15.50** |  |  |  |  |  |
| **16.00 – 16.50** |  |  |  |  |  |
| **17.00 – 17.50** |  |  |  |  |  |

**COMMITTEE I – 301 INFECTIOUS DISEASES COMMITTEE ASSESSMENT MATRIX**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **LEARNING OBJECTIVES** | **DEPARTMENT** |  |  | **Total Exam MCQs** | |  |
|  | **CE** | **FE** | **M-UE** | **TOTAL** |
| 1,4 | Medical Biochemistry |  | 2 | 0 | 0 | 2 |
| 1,2,3,4,5,6,7,9 | Medical Microbiology | 80 |  | 9 | 9 | 98 |
| 2,3,4,7 | Medical Pathology |  | 6 | 1 | 1 | 8 |
| 4,5,8 | Medical Pharmacology | 28 |  | 4 | 4 | 36 |
| 1,2,3,5,6,7,9 | Pediatrics | 5 |  | 1 | 1 | 7 |
| 1,2,3,5,6,7,9 | Internal Medicine | 1 |  | 0 | 0 | 1 |
| 3,7 | Nuclear Medicine |  | 1 | 1 | 1 | 3 |
| 7 | Clinical and Professional  Development |  | 0 | 0 | 0 | 0 |

|  |  |
| --- | --- |
| **LEARNING OBJECTIVES** | **LAB POINTS** |
| 1,2,3,4,5,6,7,9 | Medical Microbiology |
|  |  |
|  |  |
|  |  |

**Abbreviations: MCQ:** Multiple

Choice Question

**LPE:** Practical Lecture Evaluation **CE:**

CommitteeExam

**CS:** CommitteeScore

**FE:** Final Exam

**M-UE:** Make-up Exam

## COMMITTEE II – 302 Neoplasia and Hematopoietic Systems Diseases AIMS and LEARNING OBJECTIVES

**AIMS**

1. ***to remind*** knowledge of neoplasia and hematopoieticsystem,
2. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in society and/or pose high risk for subject or public health, and/or life-threatening or constitute an emergency related to neoplasia and hematopoieticsystem,
3. ***to convey*** sufficient knowledge on prevention of clinical conditions, and protection strategies of health against those clinical conditions related to neoplasia and hematopoieticsystem,
4. ***toconvey*** knowledge on mechanisms the most frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in the population and/or are the most risk for individual or community health, and/or life-threatening or constitute an emergency related to neoplasia and hematopoieticsystem,
5. ***to convey*** knowledge on pharmaceutical drugs that are effective on neoplasia and hematopoietic system or on clinical conditions involving both system diseases,
6. ***to conver*** knowledge on molecular pathogenesis of cancer and current techniques in molecular diagnosis

**LEARNING OBJECTIVES**

1. ***recall*** knowledge of neoplasia and hematopoieticsystem,
2. ***explain*** etiopathogenesis of clinical conditions (cancer, hematological syndromes, disorders and diseases, lenforeticular infections) which are frequent in society and/or pose high risk for subject or public health, and/or life-threatening or constitute an emergency related to neoplasia and hematopoieticsystem,
3. ***explain*** epidemiology of clinical conditions which are frequent in society and/or pose high risk for subject or public health, and/or life-threatening or constitute an emergency related to neoplasia and hematopoieticsystem,
4. ***explain*** prevention of clinical conditions, and protection strategies of health against those clinical conditions related to neoplasia and hematopoieticsystem,
5. ***describe*** mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. ***explain*** drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and blood products, immunomodulators) that are effective on neoplasia and hematopoietic system or on clinical conditions involving both neoplasia and hematopoieticsystem,
7. ***list*** principles of cancerchemotherapy,
8. ***explain*** chemotherapy in leukemia andlymphoma
9. ***explain*** knowledge on molecular pathogenesis of cancer and current techniques in molecular diagnosis

## COMMITTEE II – Neoplasia and Hematopoietic Systems Diseases Program 302 Neoplasia and Hematopoietic Systems Diseases

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Theoretical** | **Practical** | **Discussion** | **Total** |
| **Medical Biochemistry** | **4** |  |  | **4** |
| **Medical Microbiology** | **6** |  |  | **6** |
| **Medical Pathology** | **20** | **2** |  | **22** |
| **Medical Pharmacology** | **8** |  |  | **8** |
| **Pediatrics** | **17** |  |  | **17** |
| **Internal Medicine** | **8** |  |  | **8** |
| **Medical Biology** | **4** |  |  | **4** |
| **Nuclear Medicine** | **4** |  |  | **4** |
| **TOTAL** | **71** | **2** |  | **73** |

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Monday** | **Tuesday** | **Wednesday** | **Thursday** | **Friday** |
| **9.00-9.50** | **301**  **Committee**  **Examination** | Characteristics of benign & malignant tumors | Bilirubin  metabolism | Molecular basis of cancer II | Pathology of thymus & spleen |
| **10.00-10.50** | **301**  **Committee**  **Examination** | Spread & metastasis I | Immunity to cancers I | Immunopathology I | Pathology of lymph nodes I |
| **11.00-11.50** | **301**  **Committee**  **Examination** | T lymphocyte deficiencies | Immunity to cancers II | Immunopathology II | Pathology of lymph nodes II |
| **13.0-13.50** |  | Cancer biochemistry I | Spread & metastasis II | Antineoplastic drugs  I | Nuclear medicine in oncology |
| **14.00-14.50** |  | Cancer biochemistry II | Molecular basis of cancer I | Antineoplastic drugs  II | Pathology of bone marrow I |
| **15.00-15.50** |  | Pharmacological basis of cancer therapy | Epithelial neoplasms: Benign &  malignant | Etiology I | Pathology of bone marrow II |
| **16.00-16.50** |  | **Independent learning** | B lymphocyte deficiencies | Etiology II | Antineoplastic drugs III |
| **17.00-17.50** |  | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Monday** | **Tuesday** | **Wednesday** | **Thursday** | **Friday** |
| **09.00-9.50** | Biological effects of radiation | Immune  tolerance | Phagocytic deficiences | Mesenchimal neoplasms | LAB: Pathology neoplasia |
| **10.00-10.50** | Radiation determination, dosimetry and radiation accidents | Autoimmunity | Complement  deficiencies | Immunomodula-  tors | LAB: Pathology neoplasia |
| **11.00-11.50** | Biochemistry of tumor markers | Introduction to clinical biochemistry | **Independent learning** | Recombinant DNA derived drugs & gene therapy | Thrombosis and  fibrinolytic system |
| **13.00-13.50** | Red cell metabolism & related enzyme deficiencies and spherocytes | Hemoglobin biosynthesis | Pharmacogenomics & drug therapy | Approach to anemic patient | Leucopenia, leucocytosis, acute and chronic leucemias |
| **14.00-14.50** | Introduction to hematology and classification of anemias | Hemoglobinopathies & thallasemic syndromes | Acute leukemia | Approach to hemolitic anemias | Lymphomas |
| **15.00-15.50** | **Independent learning** | **Independent learning** | Sickle cell anemias | Transfusion and transfusion reactions bility | Chronic myeloproliferative diseases and myelodysplasic syndrom |
| **16.00-16.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | Plasma cell dyscrasias |
| **17.00-17.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Monday** | **Tuesday** | **Wednesday** | **Thursday** | **Friday** |
| **09.00-9.50** | Cancer molecular pathology and genomics  I | İndependent learnin day | Molecular pathology of cancer, in diagnosis, screening and treatment II | **Independe**  **nt learning** | İndependent learning day |
| **10.00-10.50** | Cancer molecular pathology and genomics  II |  | Tumour immunity | **Independe**  **nt learning** |  |
| **11.00-11.50** | Molecular pathology of cancer in diagnosis, screening  and treatment  I |  | Transplantation immunity | **Independe**  **nt learning** |  |
| **13.00-13.50** | Drugs used in the treatment of anemias |  | Approach to bleeding disorders | **Independe**  **nt learning** | **Independent learning** |
| **14.00-14.50** | Radiophamac euti-cals and biological principles of syntigraphy |  | Platelet | **Independe**  **nt learning** | **Independent learning** |
| **15.00-15.50** | Cancer molecular pathology and genomics  I |  | Tumors in childhood | **Independe**  **nt learning** | **Independent learning** |
| **16.00-16.50** | **Independent learning** |  | Cancer burden in the world and Turkey | **Independe**  **nt learning** | **Independent learning** |
| **17.00-17.50** | **Independent learning** | **National Holiday** | **Independent learning** | **Independe**  **nt learning** | **Independent learning** |

**Subject Committee: 302 10th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Monday** | **Tuesday** | **Wednesday** | **Thursday** | **Friday** |
| **09.00-9.50** | **Committee Examination** |  |  |  |  |
| **10.00-10.50** | **Committee Examination** |  |  |  |  |
| **11.00-11.50** | **Committee Examination** |  |  |  |  |
| **13.00-13.50** | **Committee Examination** |  |  |  |  |
| **14.00-14.50** | **Committee Examination** |  |  |  |  |
| **15.00-15.50** | **Committee Examination** |  |  |  |  |
| **16.00-16.50** | **Committee Examination** |  |  |  |  |
| **17.00-17.50** | **Committee Examination** |  |  |  |  |

**COMMITTEE II – Neoplasia and Hematopoietic Systems Diseases**

### ASSESSMENT MATRIX

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **LEARNING OBJECTIVES** | **DEPARTMENT** | |  | **Total Exam MCQs** | |  | |
| **CE** | **FE** | **M-UE** | **TOTAL** | |
| 2,5 | Medical Biochemistry | | 4 | 1 | 1 | 6 | |
| 2,35 | Medical Microbiology | | 6 | 1 | 1 | 8 | |
| 1,2,3,4,5,9 | Medical Pathology | | 20 | 3 | 3 | 26 | |
| 1,2,3,6 | Medical Pharmacology | | 8 | 1 | 1 | 10 | |
| 1,2,3,4,5,7 | Pediatrics | | 17 | 3 | 3 | 23 | |
| 1,2,3,4,5,7 | Internal Medicine | | 8 | 1 | 1 | 10 | |
| 1,2,3,9 | Medical Biology | | 4 | 1 | 1 | 6 | |
| 1,2,3,4,5,7,8 | Nucleer Medicine | | 4 | 1 | 1 | 6 | |
| **LEARNING OBJECTIVES** | | **LAB POINTS** | | | | |
| 1,2,4,5 | | **Medical Pathology** | | | | |
|  | |  | | | | |
|  | |  | | | | |
|  | |  | | | | |

**Abbreviations:**

**MCQ:** Multiple Choice

Question **LPE:** Practical Lecture Evaluation **CE:** CommitteeExam

**CS:** CommitteeScore

**FE:** Final Exam

**M-UE:** Make-up Exam

## COMMITTEE III – 303 Cardiovascular and Respiratory Systems Diseases AIM and LEARNING OBJECTIVES

**AIMS**

1. ***to remind*** generalknowledge on anatomy and histophysiology of cardiovascular and respiratory systems,
2. ***to convey*** knowledge on etiopathogenesis of clinical cardiovascular and respiratory system conditions which are commonly seen in globally as well as in the population and the most risk for individual and society health, and/or lifethreatening or constitute an emergency related to cardiovascular and respiratorysystems,
3. ***to convey*** knowledge on epidemiology of of clinical cardiovascular and respiratory system conditions which are commonly seen in globally as well as in the population and the most risk for individual and society health, and/or lifethreatening or constitute an emergency related to cardiovascular and respiratorysystems,
4. ***to convey*** fundemental knowledge on preventive approach of cardiovascular and respiratpry system clinical conditions, and protection or improvement of health against those clinical conditions,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions commonly seen in globally as well as in the population and the most risk for individual and society health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratorysystems,
6. ***toconvey***fundemental and sufficient knowledgeondrugsthat are used effectivlyoncardiovascularsystem,
7. ***to convey*** fundemental and sufficient knowledge on radiologhy and its use incardiovascular and respiratory system diseases,

**LEARNING OBJECTIVES**

1. ***recall*** anatomy and histophysiology of cardiovascular and respiratorysystems,
2. ***explain***etiopathogenesisofclinical cardiovasvular and respiratory system conditions(*upperrespiratorytractproblems-nasalobstruction,etc.-*

*,infectiousclinicalconditionswithupperandlowerrespiratorytractandlunginvolvementpneumonia, tuberculosis, etc.-, circulatory lung disorders-pulmonary embolism, etc.-, obstructive/restrictive lung diseases, respiratory insuffiency, tobacco use,lung tumors,otherlungdiseases;diseasesofcoronarycirculationandcoronaryarteries,diseasesofc ardiacvalves,myocardialandpericardialdiseases,bloodstreaminfectionsandsepsis,cardiacp roblemsinadultsand children, mediastinal diseases, nasopharyngeal and oropharyngeal diseases,nasalandparanasalsinusdiseases,diseasesofmiddleearandeustachiantube,laryn gealdiseases,voicedisorders*) which are commonly seen in globally as well as in the population and the most risk for individual and society health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratorysystems,

1. ***explain***epidemiologyofclinicalconditionswhich are commonly seen in globally as well as in the population and the most risk for individual and society health, and/or lifethreatening or constitute an emergency related to cardiovascular and respiratorysystems,
2. ***explain***fundemental knowledge on preventive approach of cardiovascular and respiratpry system clinical conditions, and protection or improvement of health against those clinical conditions,
3. ***describe*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions commonly seen in globally as well as in the population and the most risk for individual and society health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratorysystems,
4. ***explain*** drugs that are in used effectivly on cardiovascular and respiratory system diseases (autonomic system pharmacology, renin-angiotensin system pharmacology, calcium channel blockers, pharmacological approach to ischemic and congestive cardiovascular conditions, drugs effecting body fluids and volume, anti- hypertension drugs, hypolipidemic drugs, antiarrhythmic drugs, antiplatelet, antithrombotic and thrombolytic drugs, drugs used in the treatment of asthma and chronic obstructive pulmonary disease, antitussive, expectorant and surfactantdrugs),

## COMMITTEE III – 303 Cardiovascular and Respiratory Systems Diseases Program 303 Cardiovascular and Respiratory Systems Diseases

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Theoretical** | **Practical** | **Discussion** | **Total** |
| **AnesthesiologyandReanimation** | **2** |  |  | **2** |
| **Cardiology** | **22** |  |  | **22** |
| **ChestDiseases** | **7** |  |  | **7** |
| **MedicalPathology** | **19** | **5** |  | **24** |
| **MedicalPharmacology** | **18** |  |  | **18** |
| **Otorhinolaryngology** | **5** |  |  | **5** |
| **Pediatrics** | **1** |  |  | **1** |
| **Infectious Diseases & Clinical Microbiology** | **2** |  |  | **2** |
| **NuclearMedicine** | **1** |  |  | **1** |
| **Radiology** | **4** |  |  | **4** |
| **Clinicaland Professional Development** |  | **3** |  | **3** |
| **TOTAL** | **79** | **8** |  | **87** |

**Subject Committee: 303 10th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **9.00–09.50** |  | Introductiontoclinic alelectrocardiograp  hy I | Pathology of rheumatic feverandendocardit  is  Hanife Özkayalar |  | Adrenocept oragonists and antagonists  I |
| **10.00–10.50** | **302**  **Committee**  **Examination** | Introductiontoclinic  alelectrocardiograp hy II | Pathology of hypertension Hanife Özkayalar | Corpulmonalean dpulmonaryhype  rtension I Levent  Cerit | Adrenocept oragonists and  antagonists  II |
| **11.00–11.50** | **302**  **Committee Examination** | Nasal disorders | Pathology of atherosclerosis | Corpulmonalean  dpulmonaryhype  rtension II | Nuclear medicine  applications in  cardiovascu  lar  pathologies |
| **13.00–13.50** | **302**  **Committee Examination** | Diseases of larynx | Diseases of pharynx | Pathology ofischemic heartdisease | Pathology  of  pericarditis, myocarditis and cardiac tumors |
| **14.00–14.50** |  | Autonomic nervous system: General aspects | Sinusitis | Cholinergic drugs:  Muscarinicagoni sts and cholinesterasein  hibitors | Pathology of tumors of the upper respiratory tract |
| **15.00–15.50** |  | Autonomic nervous system:  Pharmacological aspects | Upperairwayobstru ctions | Muscarinicrecep torantagonists | Symptomsa  ndsigns in  chestdiseas  es I |
| **16.0–16.50** |  | **Independent learning** | **Independent learning** | **Independent learning** | Symptomsa  ndsigns in chestdiseas es II |
| **17.00–17.50** |  | **Independent learning** | **Independent learning** | **Independent learning** | **Independe**  **nt learning** |

**Subject Committee: 303 11th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **15November** |
| **9.00–09.50** | Pathology of pulmonary circulation disorders | Anticoagulant, antiplatelet and thrombolytic drugs | **National Holiday** | **Independent learning** | **Independent learning** |
| **10.00–10.50** | Pathology of  diffuse interstitial lung diseases |  | **National Holiday** | Infective  Endocarditis | **Independent learning** |
| **11.00–11.50** | Cyscticfibrosis | Pathology of lung tumors | **National Holiday** | **Independent learning** | **Independent learning** |
| **13.00–13.50** | Pathology of tuberculosis | LAB: Pathology of heart and vascular diseases I | **National Holiday** | Introduction to pediatric cardiology | **Independent learning** |
| **14.00–14.50** | Cardiogenic shock | LAB: Pathology of heart and vascular diseases II | **National Holiday** | Taking history and physcal examination | **Independent learning** |
| **15.00–15.50** | Hypertension |  | **National Holiday** | Acyanotic congenital heart diseases | **Independent learning** |
| **16.0–16.50** | Drugsused in thetreatment of dyslipidemias Ferda  Kaleağasıoğlu |  | **National Holiday** | Cyanotic congenital heart diseases | **Independent learning** |
| **17.00–17.50** | **Independent learning** | **Independent learning** | **National Holiday** | Acquired heart disease | **Independent learning** |

**Subject Committee: 303 12th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **Friday** |
| **9.00–09.50** | **Independent learning** | **Religious Holiday** | Pathology of tumors of the mediastinum and pleura | Heartfailure I | Pathology of chronicobstru ctivepulmona ry diseases I |
| **10.00–10.50** | **Independent learning** | **Religious Holiday** | Pathology of cardiac hypertrophy, dilatation and cardiomyopathy | Heartfailure II | Pathology of chronicobstru ctivepulmona ry diseases II |
| **11.00–11.50** | **Independent learning** | **Religious Holiday** | Diffuse  interstitiallungdiseas es | Molecular pathology in cardiovascular diseases I | Respiratorytr actinfections  Kaya Süer |
| **13.00–13.50** | **Independent learning** | **Religious Holiday** | Chronicobstructivep ulmonarydisaeses | Molecular pathology in cardiovascular diseases II | Environment alandoccupat ionallungdise ases |
| **14.00–14.50** | **Independent learning** | **Religious Holiday** | Pathology of nonatheroscleroticvascu lardiseases I | Drugsused in thetreatment of anginapectoris | Good  Medical  Practice |
| **15.00–15.50** | **Independent learning** | **Religious Holiday** | Pathology of nonatheroscleroticvascu lardiseases II | Arrhythmias | Good  Medical  Practice |
| **16.0–16.50** | **Independent learning** | **Religious Holiday** | **Independent learning** | **Independent learning** | Good  Medical  Practice |
| **17.00–17.50** | **Independent learning** | **Religious Holiday** | **Independent learning** | **Independent learning** | **Independent learning** |

**Subject Committee: 303 13th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **friday** |
| **9.00–09.50** | Treatment of cough, and drugsused in thetreatment of commoncold | Coronaryarterydis eases I | Drugsused in the treament of cardiac  dysrrhythmias I | Pulmonarytubercul  osis I | Drugs used in the treament of heart failure  I |
| **10.00–10.50** | Drugsused in thetreatment of asthma&chronicob structivelungdisea se | Coronaryarterydis eases II | Drugsused in the treament of cardiac  dysrrhythmias II | Pulmonarytubercul  osis II | Drug used in the treament of heart  failure II |
| **11.00–11.50** | LAB:  Pathology of heart and lungs I  Cardiomyopathy | Coronaryarterydis  eases III | Valvular heart diseases I Ümit Yüksel | Valvular heart diseases II | Radiology of the respiratory system I |
| **13.00–13.50** | LAB:  Pathology of heart and lungs II  Cardiomyopathy | Antihypertensived  rugs I | Pericarditis | Cardiopulmonary  arrest I | Radiology of the respiratory  system II |
| **14.00–14.50** | LAB:  Pathology of heart and lungs III  Cardiomyopathy | Antihypertensived rugs II | Myocarditis,  hearttumors I | Cardiopulmonary  arrest I | Effects of drugs on blood pressure and heart: Demonstrati on |
| **15.00–15.50** | Radiology of cardiovascularsyst em I  Süha Akpınar | **Independent learning** | Myocarditis, hearttumors II  Cenk  Conkbayır | **Independent learning** | **Independen**  **t learning** |
| **16.0–16.50** | Radiology of cardiovascularsyst em II  Süha Akpınar | **Independent learning** | **Independent learning** | **Independent learning** | **Independen t learning** |
| **17.00–17.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Independen t learning** |

**Subject Committee: 303 14th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **6Decem ber** |
| **9.00–09.50** |  | **Independent learning** | **Independent learning** | **Independent learning** |  |
| **10.00–10.50** |  | **Independent learning** | **Independent learning** | **Independent learning** |  |
| **11.00–11.50** |  | **Independent learning** | **Independent learning** | **Independent learning** | **Committ ee**  **Examina tion** |
| **13.00–13.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Committ ee**  **Examina tion** |
| **14.00–14.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Committ ee**  **Examina tion** |
| **15.00–15.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** |  |
| **16.0–16.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** |  |
| **17.00–17.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** |  |

## COMMITTEE III – 303 Cardiovascular and Respiratory Systems Diseases

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **LEARNING OBJECTIVES** | **DEPARTMENT** |  | **Total Exam MCQs** | |  |
| **CE** | **FE** | **M-UE** | **TOTAL** |
| 1,2,4,5,6 | Anesthesiology and Reanimation | 2 | 1 | 1 | 4 |
| 1,2,3,4,5,6 | Cardiology | 22 | 2 | 2 | 26 |
| 1,2,3,4,5,6 | Chest Diseases | 7 | 1 | 1 | 9 |
| 1,2,3,4,5 | Medical Pathology | 19 | 3 | 3 | 25 |
| 1,2,3,4,8 | Medical Pharmacology | 18 | 2 | 2 | 22 |
| 1,3,4,5 | Otorhinolaryngology | 5 | 1 | 1 | 7 |
| 1,2,3,4,5,6 | Pediatrics | 1 | 1 | 1 | 3 |
| 1,2,3,4,5 | Infectious Diseases & Clinical Microbiology | 2 | 0 | 0 | 2 |
| 1,2,3,4,5 | Nuclear Medicine | 1 | 0 | 0 | 1 |
| 1,2,3,4,5 | Radiology | 4 | 0 | 0 | 4 |
| 2,3,4 | Clinical and Professional  Development |  | 3 |  |  |
|  |  |  |  |  |  |

### ASSESTMENT SHEET

|  |  |
| --- | --- |
| **LEARNING OBJECTIVES** | **LAB POINTS** |
| 1,2,3,4,5 | Medical Pathology |
|  |  |
|  |  |
|  |  |

**Abbreviations: MCQ:** Multiple

Choice Question

**LPE:** Practical Lecture Evaluation **CE:**

CommitteeExam

**CS:** CommitteeScore

**FE:** Final Exam

**M-UE:** Make-up Exam

### 304: Gastrointestinal System Diseases AIMS and LEARNING OBJECTIVES

**AIMS**

***In evidence-based manner,***

1. ***to refresh*** the knowledge of students onanatomy, histology and physiology of gastrointestinalsystem,
2. ***to communicate*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinalsystem,
3. ***to communicate*** knowledge on epidemiology of clinical conditions which are frequent in the community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to the gastrointestinalsystem,
4. ***to communicate the*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinalsystem,
5. ***to communicate*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-

threatening or constitute an emergency related to gastrointestinalsystem,

1. ***to communicate*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to gastrointestinal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health careservice,
2. ***to communicate*** knowledge on pharmacology of drugs that are effective on gastrointestinal system or on clinical conditions involving gastrointestinalsystem,
3. ***to communicate*** knowledge on phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinalsystem,
4. ***to communicate*** knowledge on biostatistical analysis of association betweenvariables,
5. ***to communicate*** necessary knowledge on legal regulations and ethical principles for end-of-life decisions,
6. ***toequipwith***basicandadvancedclinicalskills(approachtopatientwithgast rointestinalclinical condition-C4) required at primary health care servicelevel.
7. ***to communicate*** knowledge on use of phytotherapy in an evidencebased manner and drug interactions inphytotherapy,

**LEARNING OBJECTIVES**

***At the end of this committee, student should be able to:***

1.0. ***recall*** the anatomy, histology and physiology of of the gastrointestinal system,

2.0. ***explain*** etiopathogenesis of clinical conditions (infections, nutritional disorders, bleedings, clinical conditions related to gastrointestinal organs) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system

3.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

4.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,

5.0. ***explain*** importance of healthy nutrition, principles of balanced diet, and measurement of nutritional status,

6.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

7.0. at multi-system level and/or related to gastrointestinalsystem,

* for healthy conditions in an individual or community with a request against clinical conditions that poserisks,
* in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
* for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute anemergency,

***explain*** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

* health care processes, clinical decision-making process, clinical decisions and clinical practices which are required for management at primary health care servicelevel:
  1. practice of history taking and physical examination(gastrointestinal-C4)
  2. evaluation of emergency case (acute abdominalpain-C4)
  3. approach to healthy individual or patient(diarrhea-C4)
  4. laboratorytests/examinations
  5. imaging tests/examinations (scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors- C4) 7.6. point of caretesting
  6. making preliminary diagnosis or definitive diagnosisdecision
  7. making non-intervention or interventiondecision
  8. practicing non-intervention orintervention
  9. referral/transport of healthy individual orpatient

1. ***list*** differences of gastrointestinal clinical conditions that may occur inchildren,
2. ***explain*** liver transplantation (indications, contraindications, conditions,

risks, methods, patient care, results andmonitorization),

1. ***explain*** pharmacology of drugs (agents used in the treatment of peptic ulcer, emetic and antiemetic agents, laxatives) that are effective on gastrointestinal system or on clinical conditions involving gastrointestinalsystem,
2. ***explain*** genetics of gastrointestinalsystem diseases,
3. ***explain*** phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinalsystem,
4. ***define*** the most recent techniques on thebiostatistical analysis of association betweenvariables,
5. ***talk about***the basics of legal regulations and ethical principles for end-oflifedecisions,
6. ***perform*** basic clinical skills, practiced on phantom models and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with gastrointestinal clinical condition-C4), required at primary health careservice.
7. ***to convey*** knowledge on use of phytotherapy in an evidence-based manner and drug interactions inphytotherapy.

### COMMITTEE 304–GASTROINTESTINAL SYSTEM DISEASES PROGRAM

## 304Gastrointestinal System Diseases

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Theoretical** | **Practical** | **Total** |
| **Internal Medicine** | **28** |  | **28** |
| **Medical Pathology** | **17** | **4** | **21** |
| **Medical Pharmacology** | **4** |  | **4** |
| **General Surgery** | **4** |  | **4** |
| **Radiology** | **4** |  | **4** |
| **Pediatrics** | **1** |  | **1** |
| **Clinical Microbiology& Infectious Diseases** | **3** |  | **3** |
| **Medical Genetics** | **2** |  | **2** |
| **TOTAL** | **63** | **4** | **67** |

**Subject Committee 304: 15th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **13.12.2019** |
| **9.00–09.50** | Motility disorders | Molecular Pathology of Gastrointestinal System Diseases I | Drugs used for the treatment  of peptic ulcer | Digestive and antidiarrheal drugs | Principles of the surgical treatment of gastrointestinal neoplasms I |
| **10.00–10.50** | Gastrointestinal reflux disease, Barret’s  esophagus | Personalized medicine in Gastrointestinal  System Diseases | Emetic and antiemetic drugs | Laxatives and purgatives | Principles of the surgical treatment of gastrointestinal neoplasms II |
| **11.00–11.50** | Pathology of the stomach I | Genetics and gastrointestinal system I | Brucellosis and enteric  fever | Obstructive jaundice | Principles of the surgical treatment of the colon and rectum neoplasms |
| **13.00–13.50** | Pathology of the stomach II | Genetics and gastrointestinal system II | Infections of  GIT | Hepatospleno- megaly | **Independent Learning** |
| **14.00–14.50** | Gastritis, peptic ulcer disease and  helicobacter pylorii I | **Committee Exam**  **Review Session**  **Coordinators** | Parasites that cause diarrhae | **Independent Learning** | **Independent Learning** |
| **15.00–15.50** | Gastritis, peptic ulcer disease and helicobacter pylorii II | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |
| **16.00–16.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |
| **17.00–17.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |

**Subject Committee 304: 16th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **9:00–09:50** | Polyps and  polyposıs syndroms  I | Acute and chronic  pancreatitis I | Autoımmune liver diseases | Pathology of liver cirrhosis and neoplasms I | Chronic viral  hepatitis I |
| **10:00–10:50** | Polyps and  polyposıs syndroms  II | Acute and chronic pancreatitis II | Cholestatic liver diseases (PBC,  PSK) | Pathology of liver cirrhosis and neoplasms II | Chronic viral  hepatitis II |
| **11:00–11:50** | Cancer of GIT I | Metabolic liver  diseases I | Vascular liver  diseaes | Pathology of the  liver and bile ducts  III | Pregnanacy and liver diseases |
| **13:00–13:50** | Cancer of GIT II | Metabolic liver  diseases II  (Wilson,  hemochromatos is, alpha1ATD,  NASH. ASH) | Gall bladder and biliary tract diseases | Pathology of intestinal  Neoplasms I | Pathology of oral cavity and salivary glands |
| **14:00–14:50** | Radiology of the esophagus, stomach and  duodenum | Pathology of the inflammatory bowell diseases and colon | Pathology of the liver and bile  ducts I | Pathology of intestinal  Neoplasms II | Pathology of  the esophagus |
| **15:00–15:50** | Radiology of the small bowel and colon | Radiology of diseases of liver, gall  bladder and  pancreas | Pathology of the liver and bile  ducts II | Pathology of gallbladder and  exocrine pancreas  I | **Independent Learning** |
| **16:00–16:50** | **Independent Learning** | Radiology of diseases of liver, gall  bladder and  pancreas | Pathology of malabsorption | Pathology of gallbladder and  exocrine pancreas  II | **Independent Learning** |
| **17:00–17:50** | **Independent Learning** | **Independent Learning** | **Independent Learning** |  | **Independent Learning** |

**Subject Committee 304: 17th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **9:00–09:50** | Cirrhosis and  complicatıons I | Administrative holiday | Malabsorption  syndroms I | **Independent Learning** |  |
| **10:00–10:50** | Cirrhosis and complicatıons II (portal HT / HRS / HE/ esophageal  varices/ peritonitis | Administrative holiday | Malabsorption syndroms II | **Independent Learning** | **Committe**  **e**  **Examinati on** |
| **11:00–11:50** | Liver Tumors | Administrative holiday | Inflammatory  bowel diseases I | **Independent Learning** | **Committe**  **e**  **Examinati on** |
| **13:00–13:50** | Acute liver failure and liver  transplantation I | Administrative holiday | Inflammatory  bowel diseases II | **Independent**  **Learning** | **Committe**  **e**  **Examinati on** |
| **14:00–14:50** | Acute liver failure and liver  transplantation II | Administrative holiday | LAB:  Pathology of GIT | **Independent Learning** | **Committe**  **e**  **Examinati on** |
| **15:00–15:50** | LAB:  Pathology of GIT | Administrative holiday | LAB:  Pathology of GIT | **Independent Learning** | **Committe**  **e**  **Examinati on** |
| **16:00–16:50** | LAB:  Pathology of GIT | Administrative holiday | **Independent Learning** | **Independent Learning** |  |
| **17:00–17:50** | **Independent Learning** | Administrative holiday | **Independent Learning** | **Independent Learning** |  |

### COMMITTEE 304– GASTROINTESTINAL

**SYSTEM DISEASES**

**ASSESSMENT MATRIX**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **LEARNING OBJECTIVES** | **DEPARTMENT** |  | **Total Exam MCQs** | |  |
| **CE** | **FE** | **M-UE** | **TOTAL** |
| 1.0.,2.0.,3.0.,4.0.,6.0.,7.0 | Internal medicine (Gastroenterology) | 28 | 2 | 2 | 32 |
| 2.0 6.0, 7.4 | Medical Pathology | 17 | 3 | 3 | 23 |
| 10.0 | Medical Pharmacology | 4 | 1 | 1 | 6 |
| 7.5 | Radiology | 4 | 2 | 2 | 8 |
| 5.0 | Pediatrics | 1 | 0 | 0 | 1 |
| 1.0.,2.0.,3.0.,4.0.,6.0.,7.0,  7.4 | Clinical Microbiology and Infectious Diseases | 3 | 0 | 0 | 3 |
| 11.0 | Medical Genetics | 2 | 0 | 0 | 2 |

|  |  |
| --- | --- |
| **LEARNING OBJECTIVES** | **LAB POINTS** |
| 1.0.,2.0.,3.0.,4.0.,6.0.,7.0 | **Pathology 4 hours** |
|  |  |
|  |  |
|  |  |

**Abbreviations: MCQ:** Multiple

Choice Question

**LPE:** Practical Lecture Evaluation **CE:**

CommitteeExam

**CS:** CommitteeScore

**FE:** Final Exam

**M-UE:** Make-up Exam

#### 305: Endocrine and Metabolic Diseases AIMS and LEARNING OBJECTIVES

**AIMS**

**In evidence-based manner,**

1. ***to remind*** the accumulated knowledge from anatomy, embryology, histology and physiology of the endocrine system
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in the community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to the endocrine system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or

posehighriskforindividualorcommunityhealth,and/orlife-

threateningorconstituteanemergency related to the endocrine system,

1. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to the endocrine system,
2. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in the community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to the endocrine system,
3. ***to convey the*** necessary knowledge together with the appropriate performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to endocrine and reproductive systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health careservice,
4. ***to convey*** knowledge on pharmacology of drugs that are effective on endocrine and reproductive systems or on clinical conditions involving the endocrine system,
5. ***to convey*** the knowledge on the genetics of the endocrine system,
6. ***to convey*** the knowledge on phytotherapeutic agents that are effective on endocrine system or on clinical conditions involving the endocrine system,
7. ***to convey*** the most upto date information on the design and the biostatistical analysis of survivalresearch,

**LEARNING OBJECTIVES**

***At the end of this committee, student should be able to:***

1.0. ***recall*** the anatomy, embryology, histology and physiology relevant tothe endocrine system

2.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

3.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,

4.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to the endocrine system,

5.0. at multi-system level and/or related to endocrine and reproductivesystems,

* + for healthy conditions in an individual or community with a request against clinical conditions that poserisks,
  + in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
  + for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute anemergency,

***explain*** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

* + health care processes, clinical decision-making process, clinical decisions and clinical practices which are required for management at primary health care servicelevel:

5.1evaluation of emergencycase

* 1. making preliminary diagnosis or definitive diagnosisdecision
  2. making non-intervention or interventiondecision
  3. practicing non-intervention orintervention
  4. referral/transport of healthy individual orpatient
  5. imaging tests/examinations (radiological examinations in gynecology-C5, breast imaging-C5, radioisotope imaging of thyroid and parathyroid-C5)

5.7. laboratory tests/examinations

6.0. ***explain*** pharmacology of drugs (hypothalamic and pituitary hormones, drugs effecting functions and action of oxytocin and ADH, thyroid and antithyroid drugs, adrenocortical hormones and drugs, insulin and oral antidiabetic drugs, estrogens, progestines and inhibitors) that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,

7.0. ***explain*** genetics of the endocrine system,

8.0. ***explain*** mechanisms of action for phytotherapeutic agents that are effective on endocrine system or in clinical conditions related to the endocrine system,

9.0. ***define*** design and biostatistical analysis of survival research,

10.0. ***perform*** basic clinical skills, practiced on phantom models (normal spontaneous vaginal delivery- C5), and advanced clinical skills, practiced on simulated/standardized patients required at primary health care service.

**Phase III**

## 305 Endocrine andMetabolic Diseases

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Theoretical** | **Practical** | **Discus sion** | **Total** |
| **Internal Medicine** | **32** |  |  | **32** |
| **Medical Pathology** | **9** | **2** |  | **11** |
| **Pediatrics** | **15** |  |  | **15** |
| **Medical Pharmacology** | **8** |  |  | **8** |
| **General Surgery** | **1** |  |  | **1** |
| **Radiology** | **1** |  |  | **1** |
| **Nuclear Medicine** | **1** |  |  | **1** |
| **Medical Biology** | **3** |  |  |  |
| **TOTAL** | **70** | **2** |  | **72** |

**Subject Committee: 305, 16th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDA**  **Y** | **THURSDAY** | **FRIDAY** |
| **09.00 – 09.50** |  | **New Year** | Thyroid hormone biosynthesis, metabolism  and action | Disorders of anterior hypophysis in  the adult | Dyslipidemia |
| **10.00 – 10.50** |  | **New Year** | Thyroid function tests and effects of drugs on thyroid  function | Physiopatholog y of adrenal  gland I | Hyperthyroidism I |
| **11.50 – 12.00** |  | **New Year** | Development of normal child  Neşe Akcan | Physiopatholog y of adrenal  gland II | Hyperthyroidism II |
| **13.00 – 13.50** |  | **New Year** | Thyroiditis | Growth of normal child Neşe Akcan | **Independent Learning** |
| **14.00 – 14.50** |  | **New Year** | Hypothyroidis  m | Diseases of adrenal gland I | **Independent Learning** |
| **15.00 – 15.50** |  | **New Year** | Thyroid  neoplasms | Diseases of  adrenal gland II | **Independent Learning** |
| **16.00 – 16.50** |  | **New Year** | Goiter | Physiopatholog y of adrenal  medulla | **Independent Learning** |
| **17.00 – 17.50** |  | **New Year** | **Independent Learning** | **Independent Learning** | **Independent Learning** |

**Subject Committee: 305, 17th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00 – 09.50** | Terminology in endocrinology and  clinical features | Chronic complications of diabetes  mellitus I | Endocrine  hypertension II | Pathology of hypophysis diseases | Introduction to endocrinology and hypothalamus |
| **10.00 – 10.50** | Physiopathology of Type I diabetes  mellitus | Chronic complication of diabetes  mellitus II | Polyglandular endocrine disorders | Pathology of endocrine pancreas I | Disorders of anterior hypophysis in childhood |
| **11.50 – 12.00** | Physiopathology of Type II diabetes  mellitus | Hypoglycemia | Parathyroid  diseases I | Pathology of endocrine pancreasII | Posterior hypophysis and diabetes insipidus |
| **13.00 – 13.50** | Diabetes mellitus,  signs and symptoms | Calcium & vitamin D  metabolism | Parathyroid  diseases II | Sexual  differentiation | Congenital adrenal hyperplasia |
| **14.00 – 14.50** | Nuclear medicine applications in endocrinology Deniz Bedel | Vitamin D  deficiency | Pharmacological and  pharmacokinetic  aspects of hormones | Disorders of sexual differentiation | Normal puberty |
| **15.00 – 15.50** | Acute complication  of diabetes mellitus I | Bone Biology | Anterior and posterior pituitary  hormones | İnsulin | Aberrations of puberty |
| **16.00 – 16.50** | Acute complication  of diabetes mellitus  II | Endocrine  hypertension I | **304 Committee Exam Review Session** | **Independent Learning** | The features of diabetes mellitus in childhood |
| **17.00 – 17.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** | Obesity in childhood and adolesan: evaluation and prevention |

**Subject Committee: 305, 18th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00 – 09.50** | Pathology of neuroendocrine tumors I | ACTH,  mineralocorticoids and inhibitors | Drugs affecting bone mineral homeostasis | LAB:  Pathology | **Independent Learning** |
| **10.00 – 10.50** | Pathology of neuroendocrine tumors II | Glucocorticoids | Pathology of parathyroid gland diseases | LAB:  Pathology | **Independent Learning** |
| **11.50 – 12.00** | Radiological examination of endocrine system | Molecular Basis of  Diseases of the Endocrine System | Bone health and osteoporosis in  childhood I | **Independent Learning** | **Independent Learning** |
| **13.00 – 13.50** | Thyroid surgery | Genomics of  Metabolic Disorders | Bone health and osteoporosis in  childhood II | **Independent Learning** | **Independent Learning** |
| **14.00 – 14.50** | Pathology of thyroid diseases I | Applications of  Molecular  Pathology in  Endocrine Pathology | Oral hypoglycemic  drugs | **Independent Learning** | **Independent Learning** |
| **15.00 – 15.50** | Pathology of thyroid diseases II Hanife Özkayalar | Pathology of the adrenal gland diseases | Thyroid hormones and antithyroid drugs | **Independent Learning** | **Independent Learning** |
| **16.00 – 16.50** |  | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |
| **17.00 – 17.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |

**Subject Committee: 305, 19th Week of the Academic Year**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00 – 09.50** | **Independent Learning** | **Independent Learning** |  |  |  |
| **10.00 – 10.50** | **Independent Learning** | **Committee Examination** |  |  |  |
| **11.50 – 12.00** | **Independent Learning** | **Committee Examination** |  |  |  |
| **13.00 – 13.50** | **Independent Learning** | **Committee Examination** |  |  |  |
| **14.00 – 14.50** | **Independent Learning** | **Independent Learning** |  |  |  |
| **15.00 – 15.50** | **Independent Learning** | **Independent Learning** |  |  |  |
| **16.00 – 16.50** | **Independent Learning** | **Independent Learning** |  |  |  |
| **17.00 – 17.50** | **Independent Learning** | **Independent Learning** |  |  |  |

**COMMITTEE 305–**

**ENDOCRINE AND**

### METABOLIC DISEASES

**ASSESSMENT MATRIX**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **LEARNING OBJECTIVES** | **DEPARTMENT** |  | **Total Exam MCQs** | |  |
| **CE** | **FE** | **M-UE** | **TOTAL** |
| 1.0, 2.0, 4.0 | Internal medicine (Endocrine) | 32 | 2 | 2 | 36 |
| 1.0, 2.0, 4.0, 5.0 | Medical Pathology | 9 | 1 | 1 | 11 |
| 6.0 | Medical Pharmacology | 8 | 1 | 1 | 10 |
| 5.6 | Radiology | 4 | 2 | 2 | 8 |
| 1.0, 2.0-5.0 | Pediatrics | 15 | 1 | 1 | 17 |
| 1.0-3.0 | General suregery | 1 | 0 | 0 | 1 |
| 7.0 | Medical Biology | 3 | 0 | 0 | 3 |

|  |  |
| --- | --- |
| **LEARNING OBJECTIVES** | **LAB POINTS** |
| 1.0, 2.0, 4.0, 5.7 | **Pathology 2 hours** |

#### 306 Neurological Sciences and Psychiatric Dissturbances AIMS and LEARNING OBJECTIVES

**AIMS**

**In evidence-based manner,**

1. ***to remind*** the anatomy, histology and physiology of the nervoussystem,
2. ***to convey*** the knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system andpsychiatry,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system andpsychiatry,
4. ***to convey*** necessary knowledge on the prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
5. ***to convey*** knowledge on the mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system andpsychiatry,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to nervous system and psychiatry, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health careservice,
7. ***to convey*** the necessary knowledge on drugs that are effective on nervous system or on clinical conditions related to nervous system and psychiatry,
8. ***to convey*** necessary knowledge on professional standards, organizational ethics, and ethics ofpsychiatry***,***
9. ***to convey*** necessary knowledge on common problems in medicalresearch,
10. ***to convey*** knowledge on phytotherapeuticagents,
11. ***to convey*** the information on the genetics of neurological and psychiatric dieases
12. ***to equip with*** basic and advanced clinical skills *(suturing and tyingC7, neuropsychiatric evaluation-C7)* required at primary health care servicelevel.

**LEARNING OBJECTIVES**

***At the end of this committee, student should be able to:***

1.0. ***recall*** the necessary information on anatomy, histology and physiology of nervous system,

2.0. ***define*** biochemical and psychodynamical basis of behavior,

3.0. ***grade*** physical, psychosocial and cognitive development of child,

4.0. ***explain*** etiopathogenesis of clinical conditions (central and peripheral nervous system disorders, epilepsy, organic brain syndromes, CNS tumors, psychiatric disorders/diseases) which are frequent in community and/or pose high risk for individual or community health, and/or lifethreatening or constitute an emergency related to nervous system and psychiatry,

5.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to to nervous system and psychiatry,

6.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,

7.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,

8.0. at multi-system level and/or related to cardiovascular and respiratory systemssystem,

* for healthy conditions in an individual or community with a request against clinical conditions that poserisks,
* in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
* for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute anemergency,

***explain*** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

* health care processes, clinical decision-making process, clinical decisions and clinical practices which are required for management at primary health care servicelevel:
  1. practice of history taking and physical examination(neurological/neuropsychiatric-C7)
  2. evaluation of emergency case (neurological emergencies-C7)
  3. approach to healthy individual or patient (neurological symptoms-C7, headache-C7, depression- C7, dementia-C7)
  4. laboratorytests/examinations
  5. imaging tests/examinations (conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRIC7, brain perfusion scintigraphy-C7, brain PET- C7)
  6. point of caretesting
  7. making preliminary diagnosis or definitive diagnosisdecision
  8. making non-intervention or interventiondecision
  9. practicing non-intervention orintervention
  10. referral/transport of healthy individual orpatient

9.0. ***explain*** pharmacology of drugs (parkinsonism and other movement disorders, antiepileptics, CNS stimulants and hallusinogenic drugs, sedative/hypnotic drugs, opioid analgesics and antagonists, general/local anesthetics, antipsychotic drugs, bipolar disease and lithium, antidepressant drugs, alcohols, drug dependence and abuse) that are effective on nervous system or on clinical conditions related to nervous system and psychiatry,

1. 0.***describe*** professional standards, organizational ethics, and ethics in psychiatry,
2. 0.***describe*** phytotherapeutic agents (“HMPs, Nutraceutics”),

12.0. ***list*** common problems in medical research,

13.0 ***describe*** the genetics of neurological and psychiatric conditions

13.0. ***perform*** basic clinical skills, practiced on phantom models (suturing and tying-C7), and advanced clinical skills, practiced on simulated/standardized patients (neuropsychiatric evaluation-C7), required at primary health care service.

## Phase III 306 Neurological Sciences and Psychiatric Diseases

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Theoretical** | **Practical** | **Discussion** | **Total** |
| **Anesthesiology and Reanimation** | **2** |  |  | **2** |
| **Biophysics** | **4** |  |  | **4** |
| **Medical Biochemistry** | **2** |  |  | **2** |
| **Child andAdult Psychiatry** | **3** |  |  | **3** |
| **Medical Pathology** | **14** |  |  | **14** |
| **Medical Pharmacology** | **18** |  |  | **18** |
| **Neurology** | **11** |  |  | **11** |
| **Neurosurgery** | **7** |  |  | **7** |
| **Ophthalmology** | **7** |  |  | **7** |
| **Otorhinolaryngology** | **2** |  |  | **2** |
| **Pediatrics** | **6** |  |  | **6** |
| **Psychiatry** | **11** |  |  | **11** |
| **Radiology** | **3** |  |  | **3** |
| **Medical Biology** | **3** |  |  | **3** |
| **TOTAL** | **97** |  |  | **97** |

**Subject Committee: 306 Neurological Sciences and Psychiatric Diseases**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00-09.50** | Basic cellular  reactions of  CNS I | Pathology of degenerative  diseases of the  CNS I**CCC** | Schizophrenia and other psychotic disorders: Clinical features I Ali | Muscle disorders  Amber  EkerBakkaloğlu | Neurobiology of mental illness  Kuzeymen Balıkçı |
| **10.00-10.50** | Basic cellular reactions of CNS II | Pathology of degenerative diseases of the  CNS II | Schizophrenia and other psychotic disorders: Clinical features II | Neuromuscular junction disorders | Somatoform disorders |
| **11.00-11.50** | Pathology of  CNS tumors I | Cerebrovascular diseases | Mood disorders  I: Etiology | Optic pathways and  their lesions | Motor neuron disorders |
| **13.00-13.50** | Pathology of  CNS tumors II | Epilepsy | Mood disorders  II: Clinical features | Pupil | Peripheral nervous system disorders |
| **14.00-14.50** | Pathology of infectious diseases of CNS I | Pathology of the diseases of the myelin I | Physiology of vision | Pathology of the diseases of the eye | Spinal cord disorders |
| **15.00-15.50** | Pathology of infectious diseases of CNS II | Pathology of the diseases of the  myelin II | Introduction to neurosurgery | Signs and symptoms in  psychiatry I | Epileptic syndromes of childhood |
| **16.00-16.50** | Pathology of infectious diseases of CNS III | Pathology of vascular diseases of the  CNS | Subarachnoid hemorrhage | Signs and symptoms in psychiatry II | Neuromuscular diseases |
| **17.00-17.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |

**Subject Committee: 306 Neurological Sciences and Psychiatric Diseases**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDA**  **Y** | **THURSDAY** | **FRIDAY** |
| **09.00-09.50** | Introduction to  CNS  Pharmacology I | Pharmacological aspects of general anesthesia I | **Independent Learning** | Opioid analgesics I | Drug abuse & dependence I |
| **10.00-10.50** | Introduction to  CNS  Pharmacology II | Pharmacological aspects of general anesthesia II | Pathology of toxic and metabolic diseases of the CNS | Opioid  Analgesics II | Drug abuse & dependence II |
| **11.00-11.50** | Lumbar puncture and diagnosis in CNS infections | Hypnosedatives-I | Management of acute and chronic pain I | Trinucleotide repeat disorders | Extrapyramidal system,& movement  disorders |
| **13.00-13.50** | Meningo- encephalitis in pediatric patients | HypnosedativesII & alcohol | Management of acute and chronic pain II | CNS tumors and genetics | Headache |
| **14.00-14.50** | Papilledema and papillitis | Head trauma | Dementia | Paralytic and non- paralytic strabismus I | Peripheral nerve injuries |
| **15.00-15.50** | Spine injuries | Alcohol and drug dependence | Normal fundus | Paralytic and non- paralytic strabismus II | Pediatric neurosurgery |
| **16.00-16.50** | **305 Committee Exam Review Session** | Intracranial tumors | Innervation errors of extraocular muscles | **Independent Learning** | Demyelinating disorders of CNS |
| **17.00-17.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |

**Subject Committee: 306 Neurological Sciences and Psychiatric Diseases**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | | **TUESDAY** | **WEDNESDAY** | | **THURSDAY** | **FRIDAY** |
| **09.00-09.50** | Reactive radicals in biological systems  and their actions I | | Antiparkinsoni an drugs | Antipsychotic drugs I | | Antiepileptic drugs I | **Independent Learning** |
| **10.00-10.50** | Reactive radicals in biological systems  and their actions II | | CNS  stimulants &  hallucinogenic compounds | Antipsychotic  drugs II | | Antiepileptic  drugs II | **Independent Learning** |
| **11.00-11.50** | Antidepressant drugs I | | Common  psychiatric disorders in children I | Drugs used in the  treatment of headache | | Hereditary tumor  syndromes of  CNS | Reactions to illness in child, family and physician |
| **13.00-13.50** | Antidepressant drugs II | | Common  psychiatric disorders in  children II | Degenerative spinal disorders | | Hearing losses | **Independent Learning** |
| **14.00-14.50** | Introduction to neuroradiology | | Molecular pathology of neurodegener  ative diseases | Anxiety disorders | | Otitis media | **Independent Learning** |
| **15.00-15.50** | Radiology of brain diseases | | molecular applications  in  neurodegener  ativediseases | Delirium and dementia: Etiology  and clinical symptoms | | **Independent Learning** | **Independent Learning** |
| **16.00-16.50** | Radiology of spine and spinal cord diseases | | The genetic  epidemiology  of  Neurodegene rative diseases | **Independent Learning** | | **Independent Learning** | **Independent Learning** |
|  |
|  |
| **17.00-17.50** | **Independent Learning** | **Independent Learning** | | | **Independent Learning** | **Independent Learning** | **Independent Learning** |

**Subject Committee: 306 Neurological Sciences and Psychiatric Diseases**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00-09.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |  |
| **10.00-10.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Committee Examination** |
| **11.00-11.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Committee Examination** |
| **13.00-13.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Committee Examination** |
| **14.00-14.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Committee Examination** |
| **15.00-15.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |  |
| **16.00-16.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |  |
| **17.00-17.50** | **Independent Learning** | **Independent Learning** | **Independent Learning** | **Independent Learning** |  |

### COMMITTEE 306– NEUROLOGICAL SCIENCES AND PSYCHIATRIC DISEASES ASSESSMENT MATRIX

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **LEARNING OBJECTIVES** | **DEPARTMENT** |  | **Total Exam MCQs** | |  |
| **CE** | **FE** | **M-UE** | **TOTAL** |
| 1.0, 4.0 – 8.0 | Anesthesiology and Reanimation | 2 | 1 | 1 | 4 |
| 1.0, 4.0 – 8.0 | Medical Biochemistry | 2 | 1 | 1 | 4 |
| 2.0 – 8.0, 10.0 | Child Psychiatry | 2 | 1 | 1 | 4 |
| 1.0, 4.0, 7.0 | Medical Pathology | 14 | 2 | 2 | 18 |
| 9.0 | Medical Pharmacology | 19 | 3 | 3 | 25 |
| 1.0, 4.0 – 8.0 | Neurology | 11 | 2 | 2 | 15 |
| 1.0, 4.0 – 8.0 | Neurosurgery | 8 | 1 | 1 | 10 |
| 1.0, 4.0 – 8.0 | Opthalmology | 8 | 1 | 1 | 10 |
| 1.0, 4.0 – 8.0 | Otorhinolaryngology | 2 | 2 | 2 | 6 |
| 1.0, 3.0 – 8.0 | Pediatrics | 4 | 1 | 1 | 6 |
| 1.0, 2.0, 4.0 –  8.0, 10.0 | Psychiatry | 11 | 2 | 2 | 15 |
| 8.5 | Radiology | 3 | 1 | 1 | 5 |
| 2.0, 13.0 | Medical Genetics | 2 | 0 | 0 | 2 |

### COMMITTEE 307 – UROGENITAL SYSTEM DISEASES AIM and LEARNING OBJECTIVES

#### AIM

1. ***to prompt*** anatomy, histology and physiology of urogenitalsystem,
2. ***to teach*** knowledge on histopathology and etiopathogenesis of clinical conditions, such as ones observed in community and/or pose high risk for individual, and/or life,
3. ***to teach*** prevention and protection strategies of clinical conditions related to urogenitalsystem,
4. ***to teach*** the mechanims of occurence of symptoms and findings in clinical conditions related to urogenitalsystem
5. ***to teach*** pharmacology of drugs that are effective on urogenital system or on clinical conditions involving urogenital system,
6. ***to teach*** genetics of urogenitalsystem,
7. ***to teach*** radiological examination of genitourinary system.

#### LEARNING OBJECTIVES

***Student should be able to:***

1. ***remember*** anatomy, histology and physiology of urogenitalsystem,
2. ***explain*** knowledge on histopathology and etiopathogenesis of clinical conditions, such as ones observed in community and/or pose high risk for individual, and/or life,
3. ***explain*** prevention and protection strategies of clinical conditions related to urogenitalsystem,
4. ***describe*** the mechanims of occurence of symptoms and findings in clinical conditions related to urogenitalsystem
5. ***explain*** pharmacology of drugs that are effective on urogenital system or on clinical conditions involving urogenital system,
6. ***explain***genetics of urogenitalsystem,
7. ***explain***radiological examination of genitourinary system.

**COMMITTEE 307 – UROGENITAL SYSTEM**

**DISEASES PROGRAM**

## 307 Urogenital Systems Diseases

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Theoretical** | **Practical** | **Discussio n** | **Total** |
| **General Surgery** | **1** |  |  | **1** |
| **Obstetrics and Gynecology** | **13** |  |  | **13** |
| **Urology** | **7** |  |  | **7** |
| **Medical Pathology** | **23** | **6** |  | **29** |
| **Medical Pharmacology** | **7** |  |  | **7** |
| **Pediatrics** | **13** |  |  | **13** |
| **Internal Medicine** | **8** |  |  | **8** |
| **Nuclear Medicine** | **1** |  |  | **1** |
| **Radiology** | **2** |  |  | **2** |
| **Clinical and Professional Development** | **4** |  |  | **4** |
| **Medical Genetics** | **2** |  |  | **2** |
| **Inf. Disease and Clinical Microbiology** | **1** |  |  | **1** |
| **TOTAL** | **82** | **6** |  | **88** |

### 

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00-**  **09.50** | Pathology of breastdiseases I | Role of urologist in  acuteandchronicre nalfailure  Ç. Volkan Öztekin | Independent learning | Normal labor mechanisms and phases A Cenk Özay | Pathology of urinarysystemtu mors&pediatric kidneytumors I  Hanife  Özkayalar |
| **10.00-**  **10.50** | Pathology of  breast diseases  II | Symptomsandsign  s in urology Ç. | Independent learning | Introduction to prenatal monitoring and testing | Pathology of urinarysystemtu mors&pediatric kidneytumors II |
| **11.00-**  **11.50** | Surgical approach to breast diseases | Independent learning | Endocrinology of pregnancy and physiologic changes | Introduction to genetics, structural anomaly testing and diagnosis | Pathology of urinarysystemtu mors&pediatric kidneytumors III  lar |
| **13.00-**  **13.50** | Occurence of pregnancy, detection and  fetalphysiology | Pathology of benignandmaligna ntdiseases of  uterus I | Pathology of testicular  neoplasms | Radiologicalexami nation of genitourinarysyste  m I | Anal Cytology |
| **14.00-**  **14.50** | Erectiledysfuncti on | Pathology of benignandmaligna ntdiseases of  uterus II | Pathology of gestational trophoblastic  diseases | Radiologicalexami nation of genitourinarysyste  m II | Congenitalmalf ormations of urinarysystem |
| **15.00-**  **15.50** | Independent learning | Genetical causes of habitual abortions | Urolithiasis | Concept of high risk pregnancy | The epidemiology, ethiology and patogenesis of lower genital tract |
| **16.00-**  **16.50** | Independent learning | The new concepts  on the Y chromosome | Male infertility | Independent learning | Nuclearuronep hrology |

**Subject Committee: 307 Urogenital Systems Diseases**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00-**  **09.50** | Pathology of renalglomerulardi seases I | Pathology of ovarian tumors I | Urologic oncology | Pathogenesis of glomerulonephritis I | **Independent learning** |
| **10.00-**  **10.50** | Pathology of renalglomerulardi seases II | Pathology of ovarian tumors II | Benign prostatic hyperplasia | Pathogenesis of  glomerulo-  nephritis II | Sexuallytransmi  ttedinfections |
| **11.00-**  **11.50** | Pathology of renalglomerulardi seases III | Pathology of vulva and vagina | Independent learning | Independent learning | Physiologyand methods of contraception |
| **13.00-**  **13.50** | Pathology of renalglomerular  diseases IV | Pathology of genital system infections and PID | Approach to  Dyspmorphic  Patient Panel,  SBF, Hall 3 | Basic Principles of renalphysiology I | Epidemiology, etiology and pathogenesis of endometrial neoplasia |
| **14.00-**  **14.50** | Pathology of renalglomerular diseases V | Pathology of renaltubulointerstit ialdiseases II | Independent learning | Basic Principles of renalphysiology II | Epidemiology, etiology and pathogenesis of ovarian neoplasia |
| **15.00-**  **15.50** | Pathology of renaltubulointerst  itialdiseases I | Pathology of renalvasculardisea ses | Physiology of ovulation and fertilisation | Acid-basebalance  I | Independent learning |
| **16.00-**  **16.50** | Independent learning | Independent learning | Physiology of menstrual cycle | Acid-basebalance  II | Independent learning |

**Subject Committee: 307 Urogenital Systems Diseases**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00-**  **09.50** | Independent learning | LAB:  Gynecology I  Pathology | Renaltubulardisea ses | Potassium balance and disorders | Nitricoxide |
| **10.00-**  **10.50** | Independent learning | LAB:  Gynecology II  Pathology | Hereditaryrenaldis orders | Renalinvolvement in multisystem diseases I | Independent learning |
| **11.00-**  **11.50** | Interstitialdisease s | LAB:  Gynecology III  Pathology | Sodiumandwaterb  alanceanddisorder s | Renalinvolvement in multisystem diseases II | LAB:  Urinary system  I  Pathology |
| **13.00-**  **13.50** | Interpretation of renalfunctions | Proteinuria | Acuterenalfailure  I | Independent learning | LAB:  Urinary system  II  Pathology |
| **14.00-**  **14.50** | Hypertension&cli nicalappearance | Nephroticsyndrom e | Acuterenalfailure II | Pathology of corpus uteri | LAB:  Urinary system  III  Pathology |
| **15.00-**  **15.50** | Diabeticnephrop athy | Independent learning | Diuretics I | Gynaecologic anamnesis, physical examination and  diagnostics A | Independent learning |
| **16.00-**  **16.50** | Chronicrenalfailu re:  Pathophysiology | Independent learning | Diuretics II | Independent learning | Independent learning |

**Subject Committee: 307 Urogenital Systems Diseases**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00-**  **09.50** | Clinical and professional development | Female gonadal hormones & contraceptive drugs | Independent learning | Independent learning | Independent learning |
| **10.00-**  **10.50** | Clinical and professional development | Androgens, anabolic steroids & antiandrogenic  drugs | Independent learning | Independent learning | Committee Examination |
| **11.00-**  **11.50** | Clinical and professional development | Prescription writing I | Independent learning | Independent learning | Committee Examination |
| **13.00-**  **13.50** | Clinical and professional development | Prescription  writing II | Independent learning | Independent learning | Committee |
| **14.00-**  **14.50** | Independent learning | Independent learning | Independent learning | Independent learning | Examination |
| **15.00-**  **15.50** | Independent learning | Independent learning | Independent learning | Independent learning | Committee |
| **16.00-**  **16.50** | Independent learning | Independent learning | Independent learning | Independent learning |  |

**COMMITTEE 307 – UROGENITAL SYSTEM**

**DISEASES COMMITTEE ASSESSMENT MATRIX**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **LEARNING OBJECTIVES** | **DEPARTMENT** |  | **Total Exam MCQs** | |  |
| **CE** | **FE** | **M-UE** | **TOTAL** |
| 2, 3 | **General Surgery** | **1** | **0** | **0** | **1** |
| 1, 2, 3, 4 | **Obstetrics and Gynecology** | **13** | **1** | **1** | **15** |
| 1, 2, 3, 4 | **Urology** | **7** | **1** | **1** | **9** |
| 1, 2 | **Medical Pathology** | **23** | **3** | **3** | **29** |
| 5 | **Medical Pharmacology** | **7** | **1** | **1** | **9** |
| 1, 2, 3, 4 | **Pediatrics** | **13** | **2** | **2** | **17** |
| 2, 3 | **Internal Medicine** | **8** | **1** | **1** | **10** |
| 7 | **Nuclear Medicine** | **1** | **0** | **0** | **1** |
| 7 | **Radiology** | **2** | **0** | **0** | **2** |
| 1, 2, 3, 4 | **Clinical and Professional Development** | **0** | **0** | **0** | **0** |
| 6 | **Medical Genetics** | **2** | **0** | **0** | **2** |
| 3 | **Inf. Disease and Clinical Microbiology** | **1** | **0** | **0** | **1** |

|  |  |
| --- | --- |
| **LEARNING OBJECTIVES** | **LAB POINTS** |
| 1, 2, 3, 4 | **6** |
|  |  |
|  |  |
|  |  |

**Abbreviations: MCQ:** Multiple

Choice Question

**LPE:** Practical Lecture Evaluation **CE:**

CommitteeExam

**CS:** CommitteeScore

**FE:** Final Exam

**M-UE:** Make-up Exam

**COMMITTEE 308– MUSCULOSKELETAL SYSTEM DISEASES AIM and LEARNING OBJECTIVES**

### AIM

1. ***to promt*** knowledge on anatomy, histology and physiology of musculoskeletalsystem,
2. ***to teach*** knowledge on histopathology and etiopathogenesis of clinical conditions, such as ones observed in community and/or pose high risk for individual, and/or life related to musculoskeletalsystem,
3. ***to teach*** prevention and protection strategies of clinical conditions related to musculoskeletalsystem,
4. ***to teach*** prevention and protection strategies of clinical conditions related to musculoskeletalsystem,
5. ***to teach*** the mechanims of occurence of symptoms and findings in clinical conditions related to musculoskeletalsystem,
6. ***to teach*** pharmacology of drugs that are effective on musculoskeletal system,
7. ***to teach*** necessary knowledge on ethics and deontology,
8. ***to teach*** radiological examination of musculoskeletal system and nuclear medicine,
9. ***to teach*** pathophysiology of death and forensic death, autopsy and toxicology.

### LEARNING OBJECTIVES

***Student should be able to:***

1. ***recall*** knowledge on anatomy, histology and physiology of musculoskeletalsystem,
2. ***explain*** knowledge on histopathology and etiopathogenesis of clinical conditions, such as ones observed in community and/or pose high risk for individual, and/or life related to musculoskeletalsystem,
3. ***explain*** prevention and protection strategies of clinical conditions related to musculoskeletalsystem,
4. ***explain*** prevention and protection strategies of clinical conditions related to musculoskeletalsystem,
5. ***explain*** the mechanims of occurence of symptoms and findings in clinical conditions related to musculoskeletalsystem,
6. ***explain*** pharmacology of drugs that are effective on musculoskeletal system,
7. ***explain*** necessary knowledge on ethics and deontology,
8. ***explain*** radiological examination of musculoskeletal system and nuclear medicine,
9. ***explain*** pathophysiology of death and forensic death, autopsy and toxicology.

#### COMMITTEE 308 – MUSCULOSKELETAL

**SYSTEM DISEASES**

**PROGRAM**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Theoretical** | **Practical** | **Discussion** | **Total** |
| **Physical Medicine and Rehabilitation** | **8** |  |  | **8** |
| **Medical Pathology** | **7** |  |  | **7** |
| **Medical Pharmacology** | **7** |  |  | **7** |
| **Orthopedics and Traumatology** | **8** |  |  | **8** |
| **Nuclear Medicine** | **1** |  |  | **1** |
| **Radiology** | **5** |  |  | **5** |
| **Medical Ethics and Deontology** | **7** |  |  | **7** |
| **Forensic Medicine** | **6** |  |  | **6** |
| **Sports Medicine** | **1** |  |  | **1** |
| **TOTAL** | **50** |  |  | **50** |

##### Subject Committee: 308 Musculoskeletal Systems Diseases

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00-**  **09.50** | Nonsteroidal antiinflammatory drugs I | Radiology of trauma  (soft tissue ınjury) | Radiology of trauma (fractures and dislocations) | Basic principles of rehabilitation in neurologicaldisorders | Osteoporosis – osteomalacia physiopathology  and rehabilitation |
| **10.00-**  **10.50** | Nonsteroidal antiinflammatory drugs II | Physiopathology and rehabilitation of degenerative joint diseases | Musculoskeletalra diology (infectious and metabolic diseases) | Neck and Low Back Pain and Rehabilitation Pembe | Physiopathology and  rehabilitation of nonarticular rheumatism |
| **11.00-**  **11.50** | Pathology of arthritis | Musculoskeletal system and medical rehabilitation | Introduction and classification of rheumatic diseases | Musculoskel et al radiology (tumors and tumor- likeconditions) | Bone tumors I |
| **13.00-**  **13.50** | Fracture healing and bone infections | **Independent learning** | Physiopathology and rehabilitation of sero negative  spondiloarthropath ies | Musculoskeletal radiology (arthritis and miscellaneous conditions) | Bone tumors II |
| **14.00-**  **14.50** | Sports medicine and sports traumatology | Introduction to orthopedics | Genetics andEthics | **Independent learning** | Bone tumors III |
| **15.00-**  **15.50** | Nuclear medical approach to skeletal muscleskeleton system | Bone  fracturesandfracture healing | **Independent learning** | **Independent learning** | **Independent learning** |
| **16.00-**  **16.50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** |

##### Subject Committee: 308 Musculoskeletal Systems Diseases

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09.00-**  **09.50** | **Independent learning** | **Independent learning** | Demonstration Of  musculoskeletal system drugs | **Public Holiday** |  |
| **10.00-**  **10.50** | **Independent learning** | Forensic Sciences and Forensic medicine | Principles of treatment in acute intoxications | **Public Holiday** | **Committee Examination** |
| **11.00-**  **11.50** | Soft tissue tumors  I | Pathophysiology of  Death and Forensic  Death | **Independent learning** | **Public Holiday** | **Committee Examination** |
| **13.00-**  **13.50** | Soft tissue tumors  II | Pathophysiology of  Death and Forensic Death | **Independent learning** | **Public Holiday** |  |
| **14.00-**  **14.50** | Drugs blocking neuromuscular transmission | Forensic Autopsy | **Independent learning** | **Public Holiday** |  |
| **15.00-**  **15.50** | Local anesthetic drugs | ForensicToxicology | **Independent learning** | **Public Holiday** |  |
| **16.00-**  **16.50** | **Independent learning** | ForensicCases  İdris Deniz/Deren  Çeker | **Independent learning** | **Public Holiday** |  |

**COMMITTEE 308 – UROGENITAL SYSTEM**

**DISEASES COMMITTEE ASSESSMENT MATRIX**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **LEARNING OBJECTIVES** | **DEPARTMENT** |  | **Total Exam MCQs** | |  |
| **CE** | **FE** | **M-UE** | **TOTAL** |
| 1, 4 | **Physical Medicine and Rehabilitation** | **8** | **1** | **1** | **10** |
| 1, 2 | **Medical Pathology** | **7** | **1** | **1** | **9** |
| 6 | **Medical Pharmacology** | **7** | **0** | **0** | **7** |
| 3, 4, 5 | **Orthopedics and Traumatology** | **8** | **2** | **2** | **12** |
| 8 | **Nuclear Medicine** | **1** | **0** | **0** | **1** |
| 8 | **Radiology** | **5** | **1** | **1** | **7** |
| 7 | **Medical Ethics and Deontology** | **7** | **1** | **1** | **9** |
| 9 | **Forensic Medicine** | **6** | **1** | **1** | **8** |
| 3, 4, 5 | **Sports Medicine** | **1** | **0** | **0** | **1** |

|  |  |  |
| --- | --- | --- |
|  | **LEARNING OBJECTIVES** | **LAB POINTS** |
| - |  | **-** |
|  |  |  |
|  |  |  |
|  |  |  |

**Abbreviations: MCQ:** Multiple

Choice Question

**LPE:** Practical Lecture Evaluation **CE:**

CommitteeExam

**CS:** CommitteeScore

**FE:** Final Exam

**M-UE:** Make-up Exam

### COMMITTEE 309 – PUBLIC HEALTH AIM and LEARNING OBJECTIVES

#### AIMS

1. **To gain knowledge on**the principles of public health, primary health care services, health system of different countries, health human resources,
2. **To gain knowledge on**about the performance measures on health care processes, clinicaldecision-makingprocess,andclinicalpractices,
3. **To gain knowledge on**the strategy and uses of epidemiology and research methods
4. **To gain knowledge on**about the control of communicable diseases (Acute respiratory ,diseases, diarrhoeal diseases and vector-borne diseases, investigation of epidemics
5. **To acquire information**about the financement of health care systems and universal health coverage
6. **To gain knowledge on**the environmental issues, such as environmenthealth relationship, climate change, air, indoor air and soil pollution, waste management and pesticides, environmentally induced diseases, environmental medicine, disaster medicine, school health and international health
7. **To increase** environmental awareness of the students
8. To gain knowledge on public health issues of family planning, such as rights of the woman and child, breastfeeding, infant feeding and growth monitoring and emergency contraception,
9. To gain knowledge on child health, and principles of immunisation
10. **To gain knowledge on** the epidemiology of global non-communicable diseases and their significance for public health, and to be able perform the relevant health approaches at the primary healthcare level
11. **To gain knowledgeon** the epidemiology and public health perspectives regarding prevention and rehabilitation of disability
12. **To acquire information** on definition, principles and methods of demography and the relations of demography and health
13. **To gain knowledge** of the current data on tobacco use and tobacco control,on responsibilities of physicians regarding tobacco control and to perform the relevant activitiesto patients applying to them for quitting smoking
14. **To gain knowledge** on design and biostatistical analysis of survivalresearch.

#### LEARNING OBJECTIVES

***Students should:***

1. ***explain*** the principles of public health, primary health care services, health system of different countries
2. ***explain*** about the performance measures on health care processes, clinicaldecision-makingprocess,andclinicalpractices,
3. ***explain*** the strategy and uses of epidemiology,
4. ***explain*** about the control of communicable diseases,
5. **gain knowledgeabout** financial healthcare systems and the significance of financing on universal health coverage
6. ***explain*** the environmental issues, environment-health relationship, climate change, air, indoor air and soil pollution, waste management and pesticides, environmentally induced diseases, environmental medicine,
7. ***take environmental history***
8. ***diagnose environmentally induced diseases***
9. ***organize triaje in disasters***
10. ***explain*** public health issues of family planning, such as rights of the woman and child, breastfeeding, infant feeding and growth monitoring and emergency contraception,
11. ***explain*** knowledge on design and biostatistical analysis of survivalresearch.

***Students are expected:***

1. **To acquire the knowledge of** definition, prevalence and epidemiology of NCDs, leading causes of death globally, epidemiology of leading NCDs: HT, CVD, CA, DM, COPD; economic burden of NCDs and to be able perform the relevant health approaches at the primary healthcare level for control of NCDs
2. **To acquire knowledge** of definitions, frequency, causes, prevention and rehabilitation of disability
3. ***To gain knowledge on*** population composition, data sources of demography, population movements, demographic and health surveys and current demographic-health survey of Turkey
4. ***To explain*** the rationale of tobacco control, including health and economic effects, express the role of physicians and other health professionals in tobacco control, define second-hand smoke and state the health risks and prevention of passive smoking, list the economic and industrial dimensions of tobacco use, state the global and local measures for tobacco control, explain the basic knowledge on tobacco addiction, to implement the relevant approaches for cessation, including behavioral and pharmacologic treatment

**COMMITTEE 309 – PUBLIC**

**HEALTH**

**PROGRAM**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Subject** | **Theoretical** | **Practical** | **Discussion** | **Total** |
| **Public Health** | **99** | **-** | **-** | **99** |
| **Biostatistics** | **14** | **-** | **-** | **14** |
| **Clinical and Professional Development** | **-** | **4** | **-** | **4** |
| **TOTAL** | **113** | **4** | **-** | **117** |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HOURS** | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09:00-**  **09:50** |  |  | Introduction and  Revisiting Previous  Years’ Topics-I | Primary Health  Care-I | Health Systems-  Examples |
| **10:00-**  **10:50** |  |  | Introduction and  Revisiting Previous  Years’ Topics-II | Primary Health  Care-II | Health Systems-  Examples |
| **11:00-**  **11:50** |  |  | Introduction to Public  Health | Social Determinants of Health | Control of  Diarrhoeal  Diseases |
| **13:00-**  **13:50** |  |  | Importance of Public  Health | Control of  Communicable  Diseases | Types of  Epidemiological  Studies |
| **14:00-**  **14:50** |  |  | Description, Strategy and Uses of Epidemiology | Control of  Communicable  Diseases | Types of  Epidemiological  Studies,  Descriptive  Studies |
| **15:00-**  **15:50** |  |  | Associations | Clinical and  Professional  Development | Cross-sectional  Studies |
| **16:00-**  **16:50** |  |  | Clinical and  Professional  Development | Clinical and  Professional  Development | Clinical and  Professional  Development |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HOURS** | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09:00-**  **09:50** | Tobacco Control-I | Tobacco Control-IV |  | Control of Acute  Respiratory  Infections | Health  Economics, Basic  Definitions  Economic  Evaluation in  Health Care |
| **10:00-**  **10:50** | Tobacco Control-II | Tobacco Control-V |  | Control of  Vector Borne  Diseases | Financing Health  Care Services |
| **11:00-**  **11:50** | Tobacco Control III | Tobacco Control-VI |  | Outbreak  Investigation | EnvironmentHuman Health  Relationship |
| **13:00-**  **13:50** | Measures of  Association-I | Simple and multiple  regression analysis-I |  | Cohort Studies-I | Water Pollution |
| **14:00-**  **14:50** | Measures of  Association-II | Simple and multiple  regression analysis-  II |  | Cohort Studies-II | Outdoor and  Indoor Air  Pollution |
| **15:00-**  **15:50** | Introduction to  Demography-I | Case-control  Studies-I |  | Intervention  Studies-I | Climate Change and Human Health |
| **16:00-**  **16:50** | Introduction to  Demography-II | Case-control  Studies-II |  | Intervention  Studies-II | **Independent learning** |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HOURS** | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09:00-**  **09:50** | Soil Pollution and Pesticides | Environmental  Medicine | Effects of  Excess Fertility on Women’s  &Child Health | Epidemiology of  Chronic Diseases  -I | Work-Health  Relationship |
| **10:00-**  **10:50** | Radiation and  Health | Healthy Life  Skills - General  Approach | Family Planning | Epidemiology of  Chronic Diseases-  II | Occupational  Health and  Hygiene |
| **11:00-**  **11:50** | Solid and Water  Waste | Health Human  Resources | School Health | Disability,  Prevention and  Rehabilitation  Services | Workplace  Factors,  Physical and  Chemical Factors,  Dusts-I |
| **13:00-**  **13:50** | Methodological  Studies-I | AssociationsRisk Ratios  Exercise | Disaster  Medicine I | World Child  Health  Policy/Targets | Workplace  Factors,  Physical and  Chemical  Factors,  Dusts-II |
| **14:00-**  **14:50** | Methodological  Studies-II | Health  Measurements | Disaster  Medicine II | Child Health  Indicators | Quality of  Life  t |
| **15:00-**  **15:50** | Safe  Motherhood | Logistic and  Non-linear  Regression  Analysis-I | Health  MeasurementsExercise | Child Health  Status in Turkey | Ageing in  Public  Health  Perspective |
| **16:00-**  **16:50** | Antenatal Care,  Risk Approach | Logistic and  Non-linear  Regression  Analysis-II | Health  MeasurementsExercise | Adolescent  Health | International  Health |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HOURS** | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09:00-**  **09:50** | Demography  Exercise-I | Demographic and Health Surveys:  Examples-I | Methodological  Studies-Validity  Exercise | Unwanted  Pregnancies  Exercise-I | Nutrition-related  Diseases and  Prevention |
| **10:00-**  **10:50** | Demography  Exercise-II | Demographic and Health Surveys:  Examples-II | Methodological  Studies-Validity  Exercise | Unwanted  Pregnancies  Exercise-II | Assessment of  Nutritional  Status in Risk  Groups |
| **11:00-**  **11:50** | Statistical Methods for Evaluation of Diagnostic Tests and  ROC –I | Demographic and Health Surveys:  Practice | Unwanted  Pregnancies-I | Overview of  Women’s Health | Maternal  Nutrition  During  Pregnancy and  Lactation |
| **13:00-**  **13:50** | Statistical Methods for Evaluation of Diagnostic Tests and  ROC -II | Demographic and Health Surveys:  Practice | Unwanted  Pregnancies-II | Conventions on the Rights of the  Woman and  Child | Breastfeeding, Infant Feeding and Growth  Monitoring |
| **14:00-**  **14:50** | Family Planning  Exercise-I | Survival Analysis-  I | Immunization | Occupational Diseases and accidents-I | Food Safety and  Security, Food  Additives |
| **15:00-**  **15:50** | Family Planning  Exercise -II | Survival Analysis-II | Immunization | Occupational  Diseases and  Accidents –II | Review and  Discussion-I |
| **16:00-**  **16:50** | Emergency  Contraception | **Independent learning** | Health Education and Health Promotion | Examples of Health Education and Health Promotion  Practices | Review and  Discussion-II |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HOURS** | **MONDAY** | **TUESDAY** | **WEDNESDAY** | **THURSDAY** | **FRIDAY** |
| **09:00-**  **09:50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** |  |
| **10:00-**  **10:50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Committee Exam** |
| **11:00-**  **11:50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Committee Exam** |
| **13:00-**  **13:50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Committee Exam** |
| **14:00-**  **14:50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Committee Exam** |
| **15:00-**  **15:50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** | **Committee Exam** |
| **16:00-**  **16:50** | **Independent learning** | **Independent learning** | **Independent learning** | **Independent learning** |  |

**COMMITTEE IX – PUBLIC**

**HEALTH COMMITTEE**

**ASSESSMENT MATRIX**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **LEARNING OBJECTIVES** | **DEPARTMENT** |  | **Total Exam MCQs** | |  |
| **CE** | **FE** | **M-UE** | **TOTAL** |
| 1, 2, 3, 4, 5, 6, 7 | **Public Health** | **99** | **8** | **8** | **115** |
| 8 | **Biostatistics** | **14** | **1** | **1** | **16** |
| 2, 3, 4, 7 | **Clinical and Professional Development** | **0** | **0** | **0** | **0** |

**Abbreviations: MCQ:** Multiple

Choice Question

**LPE:** Practical Lecture Evaluation **CE:**

CommitteeExam

**CS:** CommitteeScore

**FE:** Final Exam

**M-UE:** Make-up Exam

### STUDENT COUNSELLING

Student counselling aims to help students to cope up with their problems to reach their immediate or long-range personal, academic and professional goals.

The counseller will guide the student on issues leading to success, help the student for a better self-actualization and to develop a plan to overcome the difficulties he/she faces in his/her educational and social life at the Faculty.

Student counsellers will be appointed by the Dean and the lists will be announced to the academicians at the beginning of every educational year.

The student should make an appointment with the counseler who will fill the “NEU Student Counselling Form” and keep it for follow-up. This form will contain the contact information of the student and his/her parents, the date of the meeting and the issues addressed. The counseller will guide the student for orientation in the university, faculty and social facilities, regulations and ethical issues as well.

The counsellers are expected to meet the counselees at least twice a year.

The general format of the student counselling form is as following:

|  |  |
| --- | --- |
| **Near East University Faculty of Medicine Student Counselling Form** | |
| **Student Name:** | **Student No:** |
| **Phase:** | **Date of Birth (DD/MM/YY):** / / |
| **Term Address:** | **Home/Permanent Address** (if different from term address): |
| **Mobile Phone No:** | |
| **Family Details** (Name, Address, Phone No.)**:** | |
| **Details of person to contact in case of emergency** (Name, Address, Phone No) | |
| **Date of Counselling** |  |
| **Supervisor’s Name** |  |
| **DETAILS** Please detail below the main points of concern with the student’s performance, work habits, behaviour etc.: ....................... | |



**https://neu.edu.tr/ http://medicine.neu.edu.tr/**